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Abstract 
Carbohydrates are among the most abundant molecules found on the cell surfaces of 
bacteria, parasites, and viruses. Apart from the conventional roles of carbohydrates as energy 
sources and structural polymers, carbohydrates are also associated with cancer metastasis, 
protein stabilization, pathogen infection and the immune response. Cells of our body have 
sensors made out of carbohydrates on outer surface of plasma membrane and acts as sensors 
and can detect many kinds of stimuli, and can signal the immune system to respond. 
Carbohydrate-protein molecular recognition processes have pivotal roles in infections and in 
immune response to pathogens. To date, several vaccines based on isolated capsular 
polysaccharides (CPSs) are marketed against infectious diseases. However, the use of isolated 
capsular polysaccharide poses several limitations, as natural sources are generally limited and 
the isolation is very challenging. Additionally, the isolated polysaccharides are heterogeneous 
and often contains impurities. Furthermore, limited protection of certain CPS antigens 
impairs the efficiency of vaccines. To overcome limitations associated with isolated 
polysaccharides, synthetic oligosaccharides present an effective alternative with great 
potential to understand glycan immunology and rationally design effective antigens. 
Consequently, characterization and reconstruction of carbohydrate epitopes with authentic 
composition has become one of the major target in glycoscience. To this end, strategies are 
needed to facilitate the streamlined design and generation of these antigens. 
This thesis concerns the development of an effective synthetic strategy to obtain Group B 
Streptococcus (GBS) type II oligosaccharide for vaccine development. GBS, a Gram-positive 
bacterium, inhabits the intestinal and genitourinary tract of 10‐30% of humans. GBS is one of 
the primary causes of bacterial infections among neonates and pregnant women, resulting in 
many severe diseases such as sepsis, meningitis, abortion, and so on. Type II GBS is one of the 
predominant GBS serotypes and is associated with about 15% of the invasive infections in 
adults and infants; therefore, represents an important human pathogen. The development of 
effective preventive vaccine against GBS is much needed to help pregnant women protect 
their newborns. This thesis describes the effective synthetic strategy to synthesize GBS type 
II oligosaccharide to be applied for vaccine development. 
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Herein, we present a new and convenient synthesis of the repeating unit of GBS type II 
capsular polysaccharide. The structure of GBS type II was elucidated in 1983 and the repeating 
unit of GBS type II is a heptasaccharide composed of α-Neu5Ac (2-3)-ß-D-Gal-(1-4)- ß-D-
GlcNAc-(1-3)-[-ß-D-Gal-(1-6)]-ß-D-Gal-(1-4)-ß-D-Gal-(1-3)-ß-D-Glc. The presented synthetic 
strategy is based on the five subcomponents derived from the retro synthetic analysis. 
Suitably protected lactosamine and lactose derivatives are pivotal building blocks in our 
synthesis and both disaccharide fragments have been achieved from the cheap and readily 
available lactose. Having started from two disaccharides saves the efforts of glycosylation and 
reduces the number of synthetic steps. The building blocks have been obtained in good 
overall yield following the optimized synthetic approach. The synthesis of backbone linear 
chain trisaccharide [ß-D-Gal-(1-4)-ß-D-Gal-(1-3)-ß-D-Glc] and pentasaccharide [ß-D-Gal-(1-
4)-ß-D-GlcNAc-(1-3)-ß-D-Gal-(1-4)-ß-D-Gal-(1-3)-ß-D-Glc] has been achieved in excellent 
yield (~80% yield). The final steps of the synthesis comprise- the incorporation of ß-D-Gal unit 
into the linear chain pentasaccharide (currently ongoing) followed by the enzymatic 
introduction of sialic acid (NeuNAc unit) and subsequent deprotection to yield the repeating 
unit of GBS type II capsular polysaccharide.  
To conclude, in this thesis we present an efficient and easy handling synthetic approach to 
the heptasaccharide repeating unit of GBS type II. Readily available and cheap dairy side-
product lactose has been used as a key structure in the presented scheme, allowing the 
efficient synthesis of the pentasaccharide backbone of the target compound. The synthetic 
GBS II fragments will be used for glycan array and structural studies and immunochemical 
characterization with specific monoclonal antibodies. 
This thesis comprises of four main chapters and the experimental section containing the 
methods and synthetic procedures for the discussed schemes. Chapter one is a general 
introduction and deals with the necessity and the social importance of the described project. 
Chapter two of the thesis outlines the scientific background and pathogenesis of GBS, 
carbohydrates and their biological importance, and general introduction of vaccines and how 
the carbohydrates can be used as a suitable vaccine candidate. Chapter two establishes the 
importance of synthetic carbohydrates and how the synthetic carbohydrates can be used to 
develop suitable effective vaccines against GBS diseases. 
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Chapter three of the thesis contains the general introduction and structural features of GBS 
II CPS and the retrosynthetic analysis of GBS II CPS to identify the building blocks for the 
synthesis of GBS CPS II. 
Chapter four of the thesis summarizes the synthetic strategies and results to achieve the 
building blocks described in chapter three and the recombination of fragments to achieve the 
final molecule GBS II CPS repeating unit. 
The last part of the thesis will consists of the experimental methods and synthetic procedures 
to achieve the proposed molecule along with the characterization data. 
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Chapter 1 
1 General Introduction 
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1.1 Context 
The first 28 days of life, also referred to as the neonatal period, are the most vulnerable time 
for a child’s survival. Infants face the highest risk of dying in their first month of life at an 
average global rate of 18 deaths per 1,000 live births in 2017 according to UNICEF report.1 
Globally, 2.5 million children died in the first month of life in 2017 alone with approximately 
7,000 neonatal deaths every day. Most of the neonatal deaths occurred in the first day and 
week, with about 1 million dying on the first day and about one million dying within the next 
six days.1 Although under-5 mortality has declined up to 50% since 1990, 4.9 million children 
under 5 years of age died in 2015 (nearly 16,000 every day), with neonatal mortality 
accounting for approximately 45% of all deaths and with neonatal infection accounting for 
over a third of all deaths.2,3, 4 Reducing neonatal mortality is increasingly important not only 
because the proportions of under-five deaths that occur in the first 28 days is increasing as 
overall under-five mortality declines but also because the health interventions needed to 
address the major causes of neonatal deaths generally differ from those needed to address 
other under-five deaths. Despite progresses over the past quarter-century, millions of 
newborns, children and young adolescents die every year, mostly of preventable or treatable 
causes such as infectious diseases and injuries. In 2017, an estimated 6.3 million children and 
young adolescents died, mostly due to preventable causes. Children under age 5 accounted 
for 5.4 million of these deaths, with 2.5 million deaths occurring in the first month of life, 1.6 
million at age 1-11 months, and 1.3 million at age 1−4 years. An additional 0.9 million deaths 
occurred among children aged 5−14.5 These deaths reflect the limited access of children and 
communities to basic health interventions such as vaccination, medical treatment of 
infectious diseases, adequate nutrition and clean water and sanitation. Therefore, mortality 
rates among children and young adolescents are not only key indicators for child and young 
adolescent well-being, but more broadly, crucial for sustainable social and economic world. 
Two thirds of newborn deaths could be prevented if effective health interventions are 
provided during pregnancy, at birth and during the first week of life. Prevention of serious 
infections in pregnant mothers, newborns, and young infants through immunization during 
pregnancy and in early life has the potential to significantly reduce maternal and neonatal 
morbidity and mortality worldwide. Due to the recent scientific developments in the past 
decade, research in this field has advanced substantially, from the understanding of the 
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biology and immunology of pregnancy and early life, to the active development of several 
vaccine candidates. Vaccination is considered one of the most powerful means to save lives 
and to increase the level of health of humans. 
One of the leading cause of global neonatal mortality and morbidity is Group B Streptococcus 
(GBS).6 GBS was reported as a fatal human pathogen in 1938.7 GBS is a Gram-positive 
bacterium, which is generally colonized in the intestine and genitourinary tract of 10‐30 % of 
humans.8 GBS emerged as a leading cause of neonatal infections in the 1960s and is known 
to cause a wide variety of infections.9, 10 High clinical interest in GBS arises due to their ability 
to cause serious neonatal illnesses and is one of the primary causes of bacterial infections 
among neonates and pregnant women, resulting in many severe diseases such as sepsis, 
meningitis, abortion, and so on.11, 12 If pregnant women carries the GBS bacterium in her 
vagina or rectum at the time of labour and delivery, there is a 1 in 100 chance that her baby 
will become sick from GBS infection.13 The risk rises to 4% if a pregnant woman carries the 
bacterium and has certain risk factors such as- pre-term delivery before 37 weeks gestation, 
prolonged rupture of membranes (longer than 18 hrs without delivering the baby), or fever 
(38 °C or higher) during labour.14 Other risk factors include having a previous pregnancy 
resulting in a GBS infected baby or having a urinary tract infection caused by GBS. Two distinct 
clinical syndromes of invasive GBS disease in the newborns exist are early onset disease (EOD) 
and late onset disease (LOD) depending on the age of the infant at the time of disease 
manifestation. Early onset neonatal disease refers to when the infant is infected by GBS in 
the first 6 days after birth and occurs secondary to vertical transmission. EOD is characterized 
primarily by sepsis, pneumonia, or less frequently meningitis and is most likely to manifest 
within the first 12-48 hours after birth.15 About 60-70% of neonatal infections are early onset. 
Late onset neonatal disease occurs at 7-90 days after birth and are characterized by 
bacteremia, meningitis, or less commonly, organ or soft tissue infection.15, 16 Late-onset 
disease is primarily acquired by horizontal transmission from the mother, but also can be 
acquired from hospital sources or from individuals in the community.17 Late onset disease is 
less common then early onset disease. Maternal colonisation of GBS is a prerequisite for early 
onset and a risk factor for late onset disease.18 Currently there is no effective strategy to help 
pregnant woman protect their newborns from GBS, therefore, the development of effective 
preventive strategies against GBS is urgent and much needed. The health and social care cost 
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for neonates with GBS disease is high, approximately two fold higher than neonates without 
GBS disease in the first 2 years and neonatal GBS disease poses a significant burden on 
society.19 In view of this, finding prevention and treatments of morbidity for GBS-related 
diseases as well as early response and prevention is indeed an important issue that needs to 
be addressed. Finding cost-effective prevention therapies and treatments of GBS disease will 
benefit both patients and society globally. 
Currently the only prevention strategy is a carriage or risk factor-based screening followed by 
intrapartum antibiotic prophylaxis (IAP). Antibiotics can reduce the risk of GBS disease in the 
first week of life, but this approach has only been partially successful.20 Unfortunately, giving 
women antibiotics during labour is ineffective in preventing late-onset disease.21 This 
successful public health intervention remains controversial. The UK National Health Service 
does not endorse routine screening-based GBS IAP, arguing that this approach does not 
adequately meet screening appraisal criteria.22 The key issues driving the ongoing concerns 
about GBS IAP policies is due to the incomplete prevention of neonatal GBS disease.23 The 
remarkable reduction of EOD contrasts with the unchanged incidence of neonatal GBS late-
onset disease, for which IAP is not effective and for which, to our knowledge, there is no 
current prevention strategy. Vaccination presents the first step towards eliminating neonatal 
GBS disease and may be the only available approach for addressing the substantial 
international burden of GBS-associated stillbirth, preterm birth, and neonatal disease 
morbidity and mortality, therefore developing the effective vaccine against GBS is critically 
important. 
Vaccination is one of the most powerful means to save lives and to increase the level of health 
globally.24 The term vaccine elucidated by Edward Jenner's 1796 use of cowpox to immunize 
humans and providing them protection against smallpox.25 A vaccine typically contains an 
agent that resembles a disease-causing microorganism and is often made of weakened or 
killed forms of the microbe, its toxins or one of its surface proteins, and cell surface 
carbohydrates.26 This agent stimulates the body immune system to recognize the agent as 
foreign, destroy it, and keep a record of it, so that the immune system can more easily 
recognize and destroy any of such microorganisms that it encounters later. Vaccines are of 
two types- therapeutic such as vaccines against cancer, or prophylactic, which means to 
prevent or amend the effects of a future infection by any natural or wild pathogen.26 Vaccines 
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will not only reduce neonatal GBS disease, vaccination could also lead to decline in maternal 
GBS urinary tract infection and chorio amnionitis and could potentially prevent preterm birth. 
In addition, if vaccination were a reality, the complications associated with IAP such as 
maternal anaphylaxis, antibiotic resistance and changes in neonatal sepsis rates would no 
longer cause problems. 
In the last decade, the development of carbohydrate-based vaccines have successfully 
prevented many contagious diseases.27 Carbohydrates are suitable and effective candidate 
for developing vaccines as they are among the most abundant molecules found on the cell 
surfaces of bacteria, parasites, and viruses.28 Apart from their conventional roles as energy 
sources and structural polymers, carbohydrates are also associated with cancer metastasis, 
protein stabilization, pathogen infection and the immune response.29 Cells of our body have 
sensors made out of carbohydrates on outer surface of plasma membrane. These cell surface 
carbohydrates act as sensors and can detect many kinds of stimuli, and can signal the immune 
system to respond. Invading microorganisms use surface-exposed carbohydrate and protein 
molecules to adhere to target cells in order to withstand natural fluxes and perturbations. 
This initial adhesion step is considered crucial for colonization and infection by pathogenic 
bacteria, which makes this carbohydrate-protein molecular recognition process crucial in 
infections and in immune response to pathogens.30 Principally various types of cell-surface 
epitopes, characteristic of the invading organism or related to aberrant growth of cells, can 
be applied to develop vaccines.31 Consequently, characterization and reconstruction of 
carbohydrate epitopes with authentic composition has become one of the major target in 
glycoscience. Isolation of carbohydrates from natural sources represents a viable method to 
provide samples for the biological testing of these molecules.32 To date, several vaccines 
based on isolated capsular polysaccharides (CPSs) are marketed against pathogens.33, 34 
However, the use of isolated capsular polysaccharide poses several limitations, as natural 
sources are generally limited and the isolation is very challenging. Additionally, the isolated 
polysaccharides are heterogeneous and often contains impurities.33 The manufacturer of 
these vaccines still suffers from shortfalls associated with the isolation of CPSs from natural 
sources. Furthermore, limited protectiveness of certain CPS antigens attenuate the efficiency 
of vaccines. To address the shortcomings associated with isolated polysaccharides, 
alternative strategies have been developed to produce immunogenic glycan antigens. 
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Oligosaccharide synthesis has become the most promising alternative method with great 
potential to understand glycan immunology and rationally engineer efficacious antigens.35, 36 
Synthetic oligosaccharides can be produced as homogeneous compounds with well-defined 
composition with high reproducibility, very precise construct, and the variables of chain 
length and chain density can be controlled because of the product purity. Additionally, the 
vaccines based on synthetic glycans have better safety profile and optimizing the vaccine 
formulation helps to fine-tune the immune responses elicited by oligosaccharide antigens. 
The progress in establishing the structure of carbohydrate immuno-determinants in 
conjunction with advancements in carbohydrate synthesis has rendered it possible to develop 
new generations of carbohydrate based vaccines. Recent advances in chemical synthesis, 
conjugation chemistry, engineered biosynthesis, and formulation design have spawned a new 
generation of vaccines that incorporate carbohydrate antigens. To this end, strategies are 
needed to facilitate the streamlined design and generation of these antigens. Novel synthetic 
methods fuel oligosaccharide assembly. Strategies to reverse engineer antibodies enable the 
rational antigen design. Concomitantly, optimizing the vaccine formulation helps to fine-tune 
the immune responses triggered by oligosaccharide antigens. Thanks to technological 
advances in glycobiology and glycochemistry, we entered in a new scientific era in which the 
rational design of carbohydrate vaccines has become an achievable goal.  
To summarize, GBS is a dominant cause of serious neonatal illnesses especially meningitis and 
sepsis globally, and a prevention of GBS diseases is the need of the hour. Despite considerable 
advances in the diagnosis, prevention, and treatment of neonatal GBS infections, it remains 
an important public concern globally. Additionally, an increasing number of GBS infections in 
pregnant women and non-pregnant adults typically with underlying medical conditions, has 
been reported. In the first meeting of the Product Development for Vaccines Advisory 
Committee (PDVAC) by the World Health Organization (WHO) in 2014 for consultation 
regarding the development of GBS vaccines, GBS was identified as an important pathogen 
leading to a large burden of disease worldwide and a high priority for the development of a 
vaccine.37  The meeting concluded that the native CPS vaccine is ineffective due to its poor 
immunogenicity, but the immunogenicity of the GBS polysaccharide conjugate vaccine may 
be able to induce a stronger and higher functional CPS-specific response. Although 
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vaccination is the most promising strategy for the prevention of GBS infection, currently no 
licensed GBS vaccine is available on the market. 
The serious fatal threat posed by GBS on pregnant woman and neonates demands urgent 
prevention methods and carbohydrate-based vaccines present an effective solution to GBS 
diseases. This makes the development of an efficient synthetic method to obtain library of 
GBS related glycans critically demanding.  
 
 
1.2 Aim of the thesis 
Group B Streptococcus (GBS) is a leading etiologic agent of neonatal sepsis and meningitis 
and well known as one of the primary causes of bacterial infections among neonates and 
pregnant women.1, 5 GBS, according to their type specific capsular polysaccharide (CPS), has 
been classified in ten structurally and antigenically unique types (Ia, Ib ,II, III, IV, V, VI, VII, VIII, 
X). 38, 39 Among 10 distinct serotypes of GBS, 90% of EOD are caused by serotypes Ia, Ib, II, III, 
and V while LODs are caused predominantly by serotype III.40 Although all GBS serotypes are 
capable of causing invasive infection, six serotypes (Ia, Ib ,II, III, IV, V) account for the majority 
of disease both in neonates and adults. Type II GBS is associated with about 15% of the 
invasive infections in adults and infants; therefore, it represents a crucial human pathogen.41 
Carbohydrate based vaccines present a solution to prevent the diseases due to GBS. The 
growing interest of the scientific and medical community in the vaccines based on synthetic 
carbohydrate is due to their advantages with respect to vaccines prepared from natural 
isolated carbohydrates, their better efficiency, and better safety profile. Advancement in the 
field of synthetic glycochemistry makes it possible to rationally design oligosaccharide 
assembly and prepare the optimized vaccine formulation. This thesis concerns the 
development of an effective synthetic strategy to obtain Group B Streptococcus (GBS) type II 
oligosaccharides for vaccine development. The project is a part of GLYCOVAX, a European 
Training Network (ETN) funded in the framework of H2020 Marie Skłodowska- Curie ITN 
programme with the aim to rationally design well-defined and innovative glycoconjugate 
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vaccines to improve current preventive therapies for neonatal GBS infections involving 8 
academic groups and 2 industrial partners.42 
The aim of the thesis is to develop an effective synthetic strategy to obtain the repeating unit 
of GBS type II capsular polysaccharide. The structure of GBS type II was elucidated in 1983 by 
the team of professor Kasper.43 The repeating unit of GBS type II is a heptasaccharide 
consisting of α-Neu5Ac (2-3)-ß-D-Gal-(1-4)-ß-D-GlcNAc-(1-3)-[-ß-D-Gal-(1-6)]-ß-D-Gal-(1-4)-ß-
D-Gal-(1-3)-ß-D-Glc. The development of an easy handling and convenient synthetic strategy 
will include the careful retrosynthetic analysis of the GBS type II repeating unit after an 
intensive literature survey. The synthetic approach to obtain the building blocks has been 
optimized to develop a high yielding and convenient method with suitable protecting groups 
to facilitate the recombining strategy. The synthesis of backbone linear chain pentasaccharide 
[ß-D-Gal-(1-4)-ß-D-GlcNAc-(1-3)-ß-D-Gal-(1-4)-ß-D-Gal-(1-3)-ß-D-Glc] unit has been optimized 
first, and it will be followed by the incorporation of ß-D-Gal unit into the linear chain 
pentasaccharide. The enzymatic introduction of sialic acid (NeuNAc unit) into the backbone 
hexasaccharide will be carried out at University of Manchester in the research group of 
Professor Sabine Flitsch, a GLYCOVAX network partner. After achieving the fully deprotected 
GBS type II repeating unit, synthesis of a library of glycans from GBS polysaccharide type II 
will be prepared. The synthetic GBS II fragments will be used for glycan array and structural 
studies and immunochemical characterization with specific monoclonal antibodies. 
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Chapter 2 
2 GBS, Carbohydrates, & Vaccines: 
An Overview 
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Vaccination is an effective means to reduce death and morbidity caused by infectious diseases 
such as GBS infection. In recent years, the practice of vaccination with live attenuated 
bacteria, as originally conceived by Jenner to treat smallpox in 1796 and later developed by 
Pasteur, has most often left the stage to safer subunit vaccines. Subunit vaccines achieve 
protection by focusing the immune response on one or a few selected antigens. Among these, 
the structurally unique carbohydrates coating the surface of bacteria have become an optimal 
target for vaccine development.1 Since the 1970s, it has been established that the purified 
capsular polysaccharide from Streptococcus pneumoniae, Haemophilus influenzae type b 
(Hib) and Neisseria meningitidis infections could be used for the prevention of infections in 
adults. However, it was only in the 1980s that revisiting the concept of sugar conjugation to 
a carrier protein, first introduced by Avery and Goebel in the early 1930s,2 carbohydrate-
based vaccines effective in infants could also be developed. Currently, glycoconjugate 
vaccines, as the product of chemical linkage of a carbohydrate antigen to a protein, are part 
of routine vaccinations in many countries.  
This chapter will include the brief introduction of GBS, its classification and infection, GBS 
disease and preventive strategies in use, and the urgent need to develop effective preventive 
strategies against GBS. This will be followed by the brief introduction into carbohydrates and 
their role in inducing the immune system respond to pathogens and how these cell surface 
epitopes could be used to develop vaccines against a pathogen. The last section of this 
chapter will be about the origin of vaccines, their types and preparations, and general 
introduction of different type of vaccines with primary focus on carbohydrate based vaccines. 
The purpose of this chapter is to establish a correlation among carbohydrates, GBS, and 
vaccines.   
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2.1 Group B Streptococcus (GBS) 
 
 
2.1.1 History of GBS 
Streptococcus is a genus that comprises more than 50 recognized species of gram‐positive 
and spherical bacteria that are able to colonize a variety of animal hosts.3 While studying 
infections in cattle, Nocard and Mollereau identified a particular mastitis-causing 
Streptococcus in 1887, which they named Streptococcus nocardi.4 Later, this species was 
renamed Streptococcus agalactiae (from the latin meaning of “no milk”), suggesting to its 
negative impact on bovine milk production. Based on their ability to cause the lysis of red 
blood cells, streptococci were divided into two groups: β-haemolytic and nonhaemolytic. 
Later, in 1933, Rebecca Lancefield further divided β-haemolytic streptococci into several 
categories, based on a carbohydrate found in the cell surface of the bacteria.5 Hence, S. 
agalactiae is equally referred to as group B Streptococcus (GBS) as it is the only streptococcal 
species expressing the B antigen.  
 
Figure 2.1: Molecular representation of Group B Streptococcus. (Adapted from Figure 4-35a, 
Brock Biology of Microorganisms, 11th Edition, Pearson Prentice Hall, 2006) 
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They are visualized as Gram-stain positive cocci on microscopy and grow non-fastidiously as 
3-4 mm white colonies on blood agar. On a molecular level, the GBS cell surface is comprised 
of a capsule, peptidoglycan cell wall and a cell membrane (Figure 2.1).6  
In nature, this bacterium has a broad range of hosts, but is most notably known for causing 
severe infections within humans, bovines and aquatic animals.6-8 GBS inhabits the intestinal 
and genitourinary tract of 50% of humans.9 In 1938, it was first identified as a human 
pathogen, causing human fatal puerperal sepsis,10 but remained relatively unknown as 
sporadic asymptomatic cases were reported until the 1960s. By the 1970s, GBS had emerged 
as the predominant pathogen causing septicaemia and meningitis in neonates and infants, 
living in diverse regions.11-13 In the adult population, colonization is mostly asymptomatic, 
although opportunistic infections can also occur among the elderly or in 
immunocompromised individuals.14 In cattle, GBS adheres to the mammary epithelium 
causing bovine mastitis,8 while it was also found to be responsible for outbreaks of invasive 
disease in several fish farms.7 Each one of these reservoirs represents distinct ecological 
niches, reflecting the adaptive potential of GBS to very diverse host environments. Neonatal 
infections caused by GBS represent a significant cause of mortality and morbidity among 
infants. The primary clinical interest in the study of preventive strategies for GBS arises due 
to neonatal deaths caused by GBS. 
 
 
2.1.2 GBS Classification  
In the 1930s, Dr. Rebecca Lancefield described two polysaccharide antigens: the conserved 
Group B carbohydrate,5 and the diverse S substance that generates type-specific antisera. 
Since then, 10 structurally and antigenically different types of capsular polysaccharides (CPS) 
with serotypes (Ia, Ib, II, III, IV, V, VI, VII, VIII, IX), have been described.15 
Biochemical capsular polysaccharide (CPS) structure of all ten GBS serotypes has been shown 
in figure 2.2. All identified CPSs of GBS are high-molecular weight polymers with the short 
side-chain capped terminally with a sialic acid (N-acetylneuraminic acid) residue. Each CPS 
consists of variously arranged monosaccharides such as glucose (Glc), galactose (Gal), 
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rhamnose (Rha), N-acetyl glucosamine (GlcNAc), and a sialic acid (SA) residue on the 
branching terminus of the repeating unit.17 
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Figure 2.2. Chemical structure of the repeating unit of group B streptococcus (GBS) capsular 
polysaccharides. (A) Class A: GBS CPSs Ia, Ib, III, VI; (B) Class B: GBS CPSs IV, V, VII, IX; and (C) 
Class C:  GBS CPSs II, VIII. Adapted from H. S. Sheo at. al.16 
 
GBS CPSs are classified in three class depending on similarity of chemical structures and the 
involved enzymes in the assembly of the repeating units. GBS Serotypes belonging to class A 
(Ia, Ib, III, and VI) have the repeating unit which consists of two sugars containing a β (1→3) 
linked side chain and a terminal sialic acid unit (Figure 2.2 A). GBS CPS of class B (IV, V VII, and 
IX) have a repeating unit that consists of three sugars containing a β (1→6) linked side chain 
whose terminus is a sialic acid residue (Figure 2.2 B). GBS CPS type II and VIII belongs to class 
C and these CPSs have no similarity with GBS CPSs belonging to class A and class B and contain 
an α-(2→3) linked sialic acid residue (Figure 2.2 C). 
 
 
2.1.3 Virulent factors and Pathogenesis  
GBS expresses various virulence factors that are involved in its colonization, adherence, 
invasion, and immune evasion.18-20 The GBS cell surface also comprises of multiple surface-
proteins, some of which aid in the adherence of GBS to the epithelial surfaces. The virulence 
of GBS is attributed to the capsular and surface-proteins, and extracellular substances 
produced by the organism.18 Surface antigens are major contributors to the pathogenic 
potential of GBS, and one of the most important ones is the capsule polysaccharide (CPS). The 
primary step in the pathogenesis of GBS is attachment to the host, followed by replication 
and evading host defences. These virulence factors may be used as potential vaccine 
candidates. Biochemical and molecular analyses of these factors can provide a better 
understanding of the infectious process, further assisting the development of new diagnostic 
techniques, specific antimicrobial compounds, and effective vaccines.  
GBS expresses a unique CPS that is the most studied virulence factor contributing to the 
evasion of host immune defense mechanisms by protecting the bacteria from 
opsonophagocytosis by immune cells.21-23 CPS can also increase the invasiveness of GBS by 
enhancing biofilm formation, inhibiting the binding of antimicrobial peptides and neutrophil 
extracellular traps (NET), and affecting bacterial adherence to the epithelium and mucus.24-26 
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Moreover, a correlation between the presence of CPS-specific antibodies in serum and the 
increased risk of GBS EOD and LOD development was reported.27-28 Owing to its importance 
in GBS pathogenesis, CPS is considered the best target for the development of vaccine against 
GBS infection. 
The development of GBS neonatal pneumonia, septicaemia and meningitis is a complex 
process. In the pathogenesis of these diseases, the bacterial need to adhere to and penetrate 
into different host cells including the vaginal epithelium, placental membranes, respiratory 
epithelium and blood-brain barrier endothelium (Figure 2.3). When GBS get into host blood 
and deeper tissues, it will trigger the host immune responses to eradicate the bacteria. GBS 
possess virulence factors, which can help the bacteria to avoid host immune clearance and 
activate host inflammatory responses. 9 
 
Figure 2.3: Lifecycle of Group B Streptococci as a neonatal pathogen. (A) GBS maternal 
colonization in vaginal and lower gastrointestinal tracts; (B) GBS penetration of the 
intrauterine compartment; (C) Neonatal aspiration of GBS during birth;(D) GBS invade the 
neonatal lung causing pneumonia; (E) GBS arrive in the neonatal bloodstream causing sepsis; 
(F) GBS penetration of the blood-brain barrier causing meningitis. Figure adapted from L. 
Rajagopal et. al. 2009. 18 
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As per animal experiment, GBS was found in the lung, liver, spleen and brain in GBS infected 
neonatal primates.29 The symptoms of sepsis and neonatal pneumonia include hypoxemia, 
hypercapnia and apnoea. The neonatal primates died with hypotension, metabolic acidosis 
and respiratory failure after a few hours without treatment.29 There are inflammatory 
reactions and focal lesions at the early stage of GBS meningitis. This is accompanied with 
cerebral blood flow changes, cerebral hypoxia, ischaemia and oedema. This can result in 
permanent neuronal damage as necrosis in the cortex and neuronal loss and apoptosis were 
found in animal models. 30, 31 
GBS normally resides as a commensal organism in maternal genital and lower gastrointestinal 
tracts but can transits into an invasive pathogen that infiltrates a diverse array of host niches, 
such as the intrauterine compartment, neonatal lung and multiple neonatal organs, including 
the brain (Figure 2.3). This indicates that GBS is efficiently able to adapt to changing host 
environments. 
Another specific mechanism by which GBS evades innate immunity is via molecular mimicry 
of a critical host glycan. All GBS capsular polysaccharide serotypes consists of a prominent α-
(2,3)- linked terminal sialic acid in their repeat units, which is exactly same as a common host 
cell epitope present on glycolipids and glycoproteins present on the surface of all mammalian 
cells.32 
 
 
2.1.4 Invasive GBS diseases 
GBS has been identified as a major cause of invasive infections during the first three months 
of life since the 1970s. 33, 34 GBS is a cause of asymptotic bacteriuria, cystitis, and 
pyelonephritis during pregnancy. GBS bacteriuria in any concentration in a pregnant woman 
is a marker of heavy GBS colonization and bacteriuria and pyelonephritis are linked with 
preterm labour and preterm birth.35 GBS causes bacteraemia, urinary tract infection (UTI), 
chorioamnionitis, postpartum bacteraemia, and endometritis in pregnant women.36 When 
infection occurs during pregnancy, complications arise that may lead to abortion or preterm 
labour.36 
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In neonates, the most severe form of GBS infection is characterized by sepsis, pneumonia, 
and meningitis with a high fatality rate and residual damage.9 The routes of GBS infection 
include intrauterine fetal infection, ascending infection from vagina of a GBS colonized 
woman, and contamination during passage through the birth canal.35 GBS infection cases in 
the neonates and infants can be divided into two categories: early-onset disease (EOD) and 
late onset disease (LOD). Early-onset disease (EOD) is defined as presenting within the first 6 
days of life, although more than 80% of EOD cases present within the first 12 hours of birth.36 
Neonatal bacteraemia, septicaemia, pneumonia, and meningitis are the most common 
representation of early onset GBS disease.38 Risk factors for neonatal EOD include maternal 
GBS colonization, prolonged rupture of membranes, preterm delivery, GBS bacteriuria during 
pregnancy, birth of a previous infant with GBS disease, high fever, low levels of antibody to 
type specific CPS antigen, and young maternal age.39 Late-onset disease (LOD) is defined as 
illness presenting from day 7 to 89 of life, with almost half of cases presenting with meningitis. 
Late-onset disease is primarily acquired by horizontal transmission from the mother, but also 
can be acquired from hospital sources or from individuals in the community.40 Maternal 
colonization is also a strong risk factor for neonatal GBS infection in the late onset period.41 
Meningitis is the most common representation of LOD and there is risk of long-term 
neurological sequelae seems to be higher among survivors of late onset disease.  
 
 
2.1.5 Current prevention strategies 
Prevention of early-onset Group B Streptococcal infection received great clinical attention 
since GBS is the leading cause of neonatal sepsis, with a high fatality rate, especially in the 
very low birth weight infants.38 The most effective strategy to prevent GBS infections during 
the perinatal period consists in intra partum antibiotic prophylaxis, which has been 
implemented since the 1990s in some high-income countries, including France and the US.6 
For this purpose, penicillin is the most frequent treatment choice, as GBS strains are 
universally sensitive to β-lactam antibiotics.42 The pregnant women are tested for GBS 
bacteria when they are 35 to 37 weeks pregnant and giving antibiotics during labour to 
women at increased risk, including those who test positive for GBS bacteria. The revised 2010 
guidelines for the prevention of perinatal group B streptococcal disease, issued by the Centers 
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for Disease Control and Prevention (CDC), state that if a patient has a history of penicillin 
allergy, they can also give other antibiotics to women. The antibiotics help during labour only 
because the bacteria can grow back quickly and the doctors cannot give antibiotics before 
labour begins. These preventive measures have only been shown to be effective at reducing 
the risk of EOD. Unfortunately, giving women antibiotics during labour does not prevent late-
onset disease. Thus, even though there was a significant decrease in the incidence of early 
infections following the described treatment strategies, the level of LOD has remained largely 
the same.43 
 
 
2.1.6 Progress towards GBS Vaccine  
Currently, the only way to find women at risk of passing GBS onto their newborn during 
delivery is to screen for it during their third trimester of pregnancy and to monitor a course 
of antibiotics to the mother before the birth. However, this system is not foolproof and not 
practical in many overseas countries where health care systems are not as robust as in the 
western countries. 
As per meeting of the PDVAC for consultation regarding the development of GBS vaccines in 
2014,44 native CPS vaccine is ineffective due to its poor immunogenicity, but the 
immunogenicity of the GBS polysaccharide conjugate vaccine (PCV) may be able to induce a 
stronger and higher functional CPS-specific immunoglobulin G (IgG) response.45, 46 Several 
vaccine candidates are under clinical and preclinical investigations, but the low baseline 
incidence of the primary endpoint of GBS invasive disease requires phase III clinical efficacy 
trials to be very large.47 Based on a good correlation between immune response and clinical 
protection, some experts suggested that GBS vaccine can be approved based on the 
immunogenicity assay.48 Therefore, it is critical to develop a standardized immunogenicity 
assay and establish GBS serotype-specific protective cut-off values to succeed in the 
development of effective vaccines. Several efforts were made to modify the standard 
immunogenicity assay for pneumococcal PCV for the application in the GBS vaccine 
development. 
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GBS vaccine is the most promising strategy for the prevention of GBS infections in both 
newborns and adults with underlying diseases. However, numerous questions arise during 
the designing and evaluation of GBS vaccines. First, recent epidemiology studies have 
introduced the phenomenon of serotype switching and replacement occurring worldwide.49, 
50 Thus, a focused effort is required to update the global disease burden estimate and 
serotype distribution. Second, a standardized immunological assay is urgently needed. 
Hopefully, a vaccine will be soon available, to give to pregnant women the opportunity to 
prevent their newborn from GBS infection. 
 
 
 
2.2 Carbohydrates 
 
 
2.2.1 Background 
The term “carbohydrate” was first used over 100 years ago to label molecules of the sum 
formula (CH2O)n. The carbohydrates are the compounds that provide energy to living cells. 
They are compounds of carbon, hydrogen and oxygen with a ratio of two hydrogens for every 
oxygen atom. The carbohydrates we use as foods have their origin in the photosynthesis of 
plants. They take the form of sugars, starches, and cellulose. Today this term also includes 
carbohydrate derivatives and refers to the whole class of molecules. Other names for 
carbohydrates are saccharides, sugars or glycans. Chemists referred to these compounds as 
“hydrates of carbon” or “carbohydrates”. 51 The term “saccharide” was derived from the 
ancient Greek word sakhar meaning sugar or sweetness. In the 19th century, Emil Fischer 
elucidated the structure of the first monosaccharide, glucose, which was also referred as 
dextrose.52 Glucose, for example, is a common monosaccharide that is oxidized to form 
carbon dioxide and water, providing energy for cellular processes such as protein synthesis, 
movement and transport. This was the development of chirality (from the greek “cheir” 
meaning “hand”), i.e. the differentiation between the D (dexter meaning “right”) and L (laevus 
meaning “left”) forms of carbohydrates. However, at that time science was still far from 
realizing the true biological impact of carbohydrates on living organisms. 
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The four major classes of organic molecules in living systems are proteins, lipids, nucleic acids 
and carbohydrates. Carbohydrates are by far the most abundant organic molecules found in 
nature, and nearly all organisms synthesize and metabolize carbohydrates.51 The complex 
heterogeneity of carbohydrates in living systems (Fig. 2.4) is a direct result of several 
carbohydrate characteristics: the ability of different types and numbers of sugar residues to 
form glycosidic bonds with one another, the structural characteristics of these molecules, the 
type of anomeric linkage, the position and the absence or presence of branching.53, 54 
Carbohydrates play an essential part in a great deal of biological and biochemical processes. 
These molecules are commonly known as glycans in biochemical systems where they make 
up the carbohydrate chains of glycoproteins, proteoglycans and glycolipids. Glycosylation, 
substitution of these carbohydrate chains onto other molecules (most commonly proteins 
and glycolipids but also steroid skeletons), is a very common post-translational modification. 
At the most basic level, glycans are the union of saccharide chains to an underlying protein or 
lipid scaffold. Glycans are biologically important sugars, which may be single 
monosaccharides or oligosaccharides present as branched structures. About half of all known 
proteins in eukaryotes are glycosylated, indicating their importance as modifiers of different 
biological processes. Changes in oligo- or polysaccharide structures are associated with 
pathological and physiological events.55 Most commonly, glycans are linked covalently via 
glycosidic linkages to either nitrogen provided by an asparagine residue (N-linked glycans) or 
by oxygen from serine or threonine residues (O-linked glycans).54 Glycosylation of the human 
proteome is estimated to be at least 40% and glycans can comprise up to 90% of the total 
molecular weight of certain glycoproteins.56, 57 
- 25 - 
 
 
Figure 2.4: Pictorial illustration of carbohydrate heterogeneity found on cell surface 
glycoproteins and glycolipids. Sialic acids (Sia) are usually found at the terminal residue of O-
linked and N-linked glycans of glycoproteins and glycolipids. [Glc (glucose); Gal (galactose); 
Man (mannose); Fuc (fucose); GalNAc (N-acetylgalactosamine); GlcNAc (N-
acetylglucosamine)]. 
 
At least 2% of the genome is dedicated to creating, curating, maintaining, and recognizing 
glycans, and the loss of any component of these processes can result in drastic consequences 
or a threat to life.58 To date, over 100 recessive Mendelian disorders resulting from 
hypomorphic mutations in glycosylation pathways have been identified, which result in the 
group of diseases known as congenital disorders of glycosylation (CDGs).55Although, 
approximately 2% of the genome encodes the required proteins needed for normal 
glycosylation, glycan structures themselves are not encoded. Therefore, glycans are an 
important form of post-translational modification and an epigenetic mechanism that can 
regulate gene expression.  
Amazingly, glycans can be found in dense layers covering the surface of all natural cells. It is 
thought that the remarkable ubiquity of cell surface glycosylation that exists in nature is a 
consequence of its ability to shield a host cell from pathogens that would otherwise quickly 
adapt to recognize cell surface proteins.59 Glycans are a common point of attachment for 
invading pathogens but can be rapidly remodeled without sacrificing underlying protein 
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function. Compared to the relatively limited diversity of linear structures achievable with any 
given quantity of amino acids, orders of magnitude more structures are possible with the 
same number of monosaccharides.60 
Our understanding of the different glycoconjugates present on cells, proteins and entire 
organisms is lagging far behind compared to the advances in genomics and proteomics. 61, 62 
Carbohydrate sequencing and advancement in the synthesis of defined oligosaccharides are 
two key approaches that have contributed to progress in glycomics research. Synthetic tools 
and high-throughput experiments such as carbohydrate arrays are beginning to affect 
biological research. These techniques are now being applied to the development of 
carbohydrate-based diagnostics, vaccines and therapeutics. 63 
 
 
2.2.2 Carbohydrates and Immunity 
The immune system refers to a collection of cells and proteins that function to protect the 
skin, respiratory passages, intestinal tract and other areas from foreign antigens (any 
molecule recognized by the immune system as a foreign invader or as potentially dangerous 
for the host) such as microbes (organisms such as bacteria, fungi, and parasites), viruses, 
cancer cells, and toxins. The immune system responds to antigens by prompt an appropriate 
immune response. Protective immunity against pathogen exposure is attained by the 
amalgation of two distinct arms of the immune response (although these distinctions are not 
mutually exclusive): the innate and the adaptive (antigen-specific) responses.64 Innate 
immunity refers to nonspecific defense mechanisms that come into play immediately or 
within hours of an antigen's appearance in the body.65 These mechanisms include physical 
barriers such as skin, chemicals in the blood, and immune system cells that attack foreign cells 
in the body. The innate immune response is activated by chemical properties of the antigen. 
The innate response is rapid and unspecific and it is mediated by antigen-presenting cells 
(APCs) and establishes the first line of immune defense, detecting and responding to 
pathogen-associated molecular patterns (PAMPs).65, 66 Adaptive immunity is an antigen-
specific immune response and is more complex than the innate.67 The antigen first must be 
processed and recognized. Once an antigen has been recognized, the adaptive immune 
system creates an army of immune cells specifically designed to attack that antigen. Thymus 
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cells (T cells) and bone marrow- or bursa-derived cells (B cells) mediate the adaptive response. 
The adaptive response recognizes pathogens with high affinity, providing the fine antigenic 
specificity required for complete elimination of the infective agent and the generation of the 
immunological memory. Adaptive immunity also includes a "memory" that makes future 
responses against a specific antigen more efficient.67 
B and T cells are the major cellular components of the adaptive immune response. T cells are 
involved in cell-mediated immunity, whereas B cells are primarily responsible for humoral 
immunity (relating to antibodies). The function of T cells and B cells is to recognize specific 
"non-self" antigens, during a process known as antigen presentation. Once they have 
identified an invading pathogen, the cells produce specific responses that are optimized to 
eliminate specific pathogens or pathogen-infected cells. B cells respond to pathogens by 
producing large quantities of antibodies that further neutralize foreign objects like bacteria 
and viruses. In response to pathogens, some T cells, called T helper cells (Th cells), produce 
cytokines that direct the immune response while other T cells, called cytotoxic T cells, produce 
toxic granules that contain powerful enzymes that can induce the death of pathogen-infected 
cells. Following activation, B cells and T cells leave a lasting legacy of the encountered antigens 
in the form of memory cells. Throughout the lifetime of an animal, these memory cells will 
remember each specific pathogen encountered, and are able to mount a strong and rapid 
response if the same pathogen is detected again; this is known as acquired immunity. 
Since carbohydrates are common surface molecules, it is reasonable to postulate that they 
are critical for immune recognition. Glycans influence immunity by regulating signal 
transduction and receptor activation, protein folding, and cell adhesion. Recent genomic 
studies have revealed the presence of carbohydrate recognition domains (CRDs) throughout 
evolution, suggesting an important role for glycans and their recognition in physiology. 68, 69 
Pathogens are decorated with structurally distinct surface glycans and there are accumulating 
evidences have been demonstrating the importance of glycans and glycans binding proteins 
in the regulation of both innate and adaptive immune responses recognized by the immune 
system.70 The chemically synthesized cell-surface glycans of clinically relevant bacterial and 
parasitic pathogens can be exploited as immunogens for vaccination. Chemically synthesized 
cell-surface glycans allow the generation of highly specific antibody responses to complex 
glycan structures. With the common presence of carbohydrate molecules on eukaryotic, 
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prokaryotic, and viral surfaces, the impact of carbohydrates on adaptive immunity is now 
indisputable. 
 
 
2.2.3 Role of Carbohydrates 
A dense layer of oligosaccharides, also referred to as glycocalyx, covers the surrounding 
membranes of mammalian cells and some bacteria.71 Most human epithelia cells have a 
glycocalyx coating on the external surface of their plasma membranes.72 This coating consists 
of several carbohydrates moieties, such as membrane glycolipids,72 glycoproteins,73 
proteoglycans,74 and other types of glyco-conjugates. These carbohydrates moieties display 
a remarkable degree of structural diversity and complexity. In general, these molecules 
contribute to cell-cell recognition, communication, and intercellular adhesion. Carbohydrate-
specific receptors are called lectins,75 that are found on the cell surface. They can interact 
with carbohydrates on correspondent cells. This process may control the adhesion of cells, 
such as carbohydrate-directed cell adhesion,76 and it appears to be important in many 
intercellular activities including infection by bacteria77 and viruses,78 communication among 
cells of lower eukaryotes,79 specific binding of sperm to eggs,80 and recirculation of 
lymphocytes,81 among others. An increasing number of studies demonstrate that 
carbohydrates play a very important role in both inter and intra cellular signal transmission.82 
Additionally, manipulation of relevant carbohydrate moieties may potentially impact or alter 
certain biological recognition events.83  
Glycans are often large, highly charged structures. When positioned at the cell surface, they 
are uniquely poised to mediate the interaction of the cell with the outside environment. They 
can promote or obstruct interactions of receptors and their ligands, or alternatively of glycan-
binding proteins known as lectins.84 The structural variability and complexity of cell surface 
glycans allows them to function as signaling molecules, recognition molecules and adhesion 
molecules.85-87 As such, cell surface glycans are involved in many physiologically important 
functions that include normal embryonic development, differentiation, growth, contact 
inhibition, cell-cell recognition, cell signaling, host-pathogen interaction during infection, host 
immune response, disease development, metastasis, intracellular trafficking and localization, 
rate of degradation and membrane rigidity.85, 88-96 Although the physical and chemical 
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properties of simple carbohydrates are well known, it is unfortunate that we cannot say the 
same for complex carbohydrates in living systems. Glycobiology is a fertile area that we are 
just beginning to understand and appreciate. Studies in glycobiology have been advancing at 
ever-increasing rates in the past few years driven by advanced developments in new 
technologies and in genomics.97, 98 
 
 
2.2.4 Carbohydrates as a vaccine candidate 
The structural complexity of carbohydrate moieties on glycocalyx made them become 
possible bio-markers/antigen for vaccine or monoclonal antibodies development.99, 100 There 
are some very successful examples of licensed vaccines that target carbohydrate antigens. 
For example, Pneumovax® 23 (PPV-23) is a 23-valent pneumococcal vaccine derived from 
capsular polysaccharides.101, 102 Compared to proteins, carbohydrates are more conserved 
and more abundant on the cell surface. Consequently, development of carbohydrate-based 
vaccines against various diseases has been a hot area in recent decades, and many new and 
highly effective vaccines have been developed.103-105 
The development of vaccines based on carbohydrates has a long history. As early as 1923, 
Heidelberger and Avery 106 described a ‘soluble specific substance’, of pneumococci to consist 
most likely of polysaccharides (PSs) and being typical for the serotype. Francis and Tillett 107 
noted that intradermal injections of type-specific polysaccharides induced the development 
of circulating antibodies for heterologous types of Pneumococci. Later, Heidelberger et al. 108 
established that pneumococcal capsular polysaccharides could be used as vaccines, providing 
a long lasting immunity. Despite the potential to apply such compounds as vaccines, the 
development of chemotherapeutics and antibiotics has led to a loss of interest in this 
application. Renewed interest for preventive vaccination was induced by the steady increase 
in resistance towards antibiotics. In 1983, Pneumovax was introduced, being a capsular 
polysaccharide vaccine derived from 14 pneumonia serotypes. Subsequently, Pneumovax 23 
was presented containing isolated polysaccharides from 23 serotypes out of the about 90 
known.109, 110 
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The cell surfaces of bacteria, parasites and viruses exhibit oligosaccharides that are often 
distinct from those of their hosts. Specific types of glycoconjugate are often more highly 
expressed on the surface of tumors than on normal cells. 111 Such cell-surface carbohydrate 
markers are the basis for carbohydrate-based detection systems and vaccines. An immune 
response against the carbohydrate antigens that results in the death of target cells is required 
for a carbohydrate-based vaccine. Such vaccines have been widely used against a host of 
diseases for several decades112. The carbohydrate antigens for antibacterial vaccines were 
isolated from biological sources. Recently, intense efforts focused on the use of defined 
carbohydrate antigens that are synthesized rather than isolated. A carbohydrate-based 
approach has also been pursued for anticancer vaccine candidates.113-115  
Recently, intense efforts focused on the use of defined carbohydrate antigens that are 
synthesized rather than isolated from natural CPSs because of their limited availability and 
challenging isolation. The first commercial vaccine containing a synthetic carbohydrate 
antigen was developed in Cuba against Hib.116 This vaccine, QuimiHib®, exhibits several 
advantages associated because of the use of the synthetic carbohydrate: potentially lower 
production costs compared to conventional vaccines using carbohydrates from natural 
sources, controlled production of a homogeneous single compound including the linker, 
minimal batch-to-batch inconsistency during manufacturing process, and higher quality 
control standards are permitted, compared with the use of naturally derived agents. In 
addition, synthetic carbohydrates can be modified to increase their immunogenicity. 
Vaccine development could benefit greatly from the new glycomics technologies. The 
identification of specific oligosaccharide antigens has been aided substantially by sequencing 
and carbohydrate arrays. The procurement of defined oligosaccharides using improved 
solution- and solid-phase methods has become fast enough to be used reiteratively in drug-
development efforts. A barrier to development of carbohydrate vaccines has been the lack of 
robust technologies that support the production of synthetic vaccines and analysis of the 
specificity of an immune response. Many scientific efforts have focused on advances in the 
synthesis, analysis of carbohydrates and analysis of carbohydrate immune responses that 
promise to accelerate the development of carbohydrate vaccines. This makes the 
development of new methods for oligosaccharide synthesis very lucrative and important.  
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2.3 Vaccines 
 
 
2.3.1 History 
Vaccines have been one of the biggest success stories of modern medicine. Vaccination is an 
effective means to reduce death and morbidity caused by infectious diseases. WHO estimates 
that at least 10 million deaths were prevented between 2010 and 2015, thanks to 
vaccinations delivered around the world. Many millions more lives were protected from the 
suffering and disability associated with diseases such as pneumonia, diarrhea, whooping 
cough, measles, and polio. It is not difficult to imagine the impact of vaccination if we just 
think that in the 20th century smallpox alone killed 300 million people, and that no one dies 
from it today because the virus has been eradicated thanks to vaccination in 1978.117 
Worldwide life expectancy also increased moving from 58.5 to 70 years from 1970 through 
2010.118 The highest decrease in mortality was measured in children and young adults up to 
20 years of age. During this period, the Expanded Program on Immunization and more 
recently the establishment of the Global Alliance for Vaccines and Immunization (GAVI) 
increased complete infant immunization from less than 5% to more than 90%.119 A study from 
the World Health Organization (WHO), reports that today vaccines save more than 2.5 million 
deaths annually.120 The impact of communicable diseases worldwide decreased from 33% of 
the total deaths in 1990 to 25% in 2010 and non-communicable diseases became the first 
cause of global mortality and morbidity.121 
The human immune system can detect a variety of pathogens and distinguish them from 
normal healthy tissues. The recognition of pathogenic patterns leads to the development of 
multiple highly specific defense mechanisms that eradicate or neutralize the pathogens in 
body. By harnessing the power of the immune system, vaccines have become one of the most 
significant achievements in the history of medical practice.122 In 1796, Edward Jenner first 
inoculated healthy patients with a less lethal cowpox virus to help induce immunity against 
the smallpox virus.123 Numerous successes post-Jenner have proven the great value of 
vaccines to society. Once the microbial origin of infectious diseases was discovered a century 
later, Pasteur pioneered vaccine development by exposing people to dead or attenuated 
microorganisms that mimicked the infectious agent, but did not cause disease.124, 125 In the 
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1940s the discovery that viruses could be grown in in vitro cultures on animal cells allowed 
the development of many vaccines against poliomyelitis, measles, mumps, rubella, varicella, 
hepatitis A and, more recently, rotavirus and influenza. For more than a century vaccines have 
been developed following the principles of Pasteur by isolating, inactivating, and injecting the 
microorganism causing the disease or a portion of it. 124, 125 During the last 30 years, several 
new and unconventional technologies allowed for the development of vaccines that 
conquered several diseases.44, 126 The advent of recombinant DNA in the late 1970s made it 
possible to safely make large quantities of hepatitis B vaccine by producing it in yeast viral-
like particles (VLPs) identical to those released in the plasma by the hepatitis B virus.127  
Currently there are several types of vaccines available in the medical practice, including 
attenuated or dead microorganisms, inactivated bacterial toxins, protein subunit, and 
capsular polysaccharides. Most of the successful vaccines in clinical applications are targeting 
epidemic diseases and have been developed empirically. For example, influenza vaccines are 
developed based on the specific influenza virus subunits, which are reconfigured regularly.  
 
 
2.3.2 Type of Vaccines 
The first human vaccines against viruses were based using weaker or attenuated viruses to 
generate immunity. The smallpox vaccine used cowpox, a poxvirus that was similar enough 
to smallpox to protect against it but usually did not cause serious illness.123 Rabies was the 
first virus attenuated in a lab to create a vaccine for humans.128 Vaccines are made using 
several different processes. They may contain live viruses that have been attenuated 
(weakened or altered so as not to cause illness); inactivated or killed organisms or viruses; 
inactivated toxins (for bacterial diseases where toxins generated by the bacteria, and not the 
bacteria themselves, cause illness); or merely segments of the pathogen (this includes both 
subunit and conjugate vaccines).126 
There are several different types of vaccines. Each type is designed to teach to your immune 
system how to fight off certain kinds of pathogens and the serious diseases they cause. While 
creating vaccines, few factors must be considered such as- how your immune system 
responds to the pathogen, who needs to be vaccinated against the germ, the best technology 
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or approach to create the vaccine. Based on a number of these factors, scientists decide which 
type of vaccine needs to be developed. There are 4 main types of vaccines based on different 
preparation methods:  
 
2.3.2.1 Live-attenuated vaccines  
The idea of attenuation of virulent infections developed slowly over the course of centuries. 
Variolation was analogous to the use of small amounts of poison to render one immune to 
toxic effects. Jenner’s use of an animal poxvirus (probably horsepox) to prevent smallpox was 
essentially based on the idea that an agent virulent for animals might be attenuated in 
humans. Live attenuated vaccines contain whole bacteria or viruses, which have been 
weakened so that they create a protective immune response but do not cause disease in 
healthy people. The immune response to a live attenuated vaccine is virtually identical to that 
produced by a natural infection. The immune system does not differentiate between an 
infection with a weakened vaccine virus and an infection with a wild virus. Live vaccines tend 
to create a strong and lasting immune response and are some of our best vaccines. Protection 
from a live, attenuated vaccine typically outlasts the protection provided by a killed or 
inactivated vaccine. Live attenuated vaccines are used against measles, mumps, rubella, 
yellow fever, rotavirus, smallpox, chickenpox, and influenza. 129, 130 
However, live vaccines are not suitable for people whose immune system does not work, due 
to either drug treatment or underlying illness. Live attenuated vaccines may cause severe or 
fatal reactions because of uncontrolled replication of the vaccine virus. This only occurs in 
persons with immunodeficiency (e.g., from leukemia, treatment with certain drugs, or human 
immunodeficiency virus [HIV] infection). This is because the weakened viruses or bacteria can 
multiply too much and might cause disease in these people.  
 
 
2.3.2.2 Inactivated vaccines 
One alternative to attenuated vaccines is a vaccine from killed or inactivated pathogen. 
Vaccines of this type are created by inactivating a pathogen, typically using heat or chemicals 
such as formaldehyde or formalin. This destroys the pathogen’s ability to replicate, but keeps 
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it intact so that the immune system can still recognize it. Inactivated is generally used rather 
than killed to refer to viral vaccines of this type, as viruses are generally not considered alive. 
Because killed or inactivated pathogens can not replicate at all, they cannot cause the 
diseases against which they protect, even in people with severely weakened immune 
systems. However, they tend to provide a shorter length of protection than live vaccines, and 
are more likely to require boosters to create long-term immunity. Therefore, you may need 
several doses over time (booster shots) in order to get ongoing immunity against diseases.  
Inactivated vaccines usually do not provide immunity (protection) that is as strong as live 
vaccines. In addition, inactivated vaccines usually require higher doses and multiple boosters, 
possibly causing inflammatory reactions at the site of injection. Adjuvants such as aluminium 
salts are often added to inactivated vaccines. These are substances, which help to strengthen 
and lengthen the immune response to the vaccine. As a result, common local reactions, such 
as a sore arm, may be more noticeable and frequent with inactivated vaccines. Inactivated 
vaccines are used to protect against Hepatitis A, Flu, Polio, and Rabies. 129, 130 
 
 
2.3.2.3 Toxoid vaccines 
Some bacterial diseases are not directly caused by a bacterium itself, but by a toxin produced 
by the bacterium. The immune system recognises these toxins in the same way that it 
recognises polysaccharides or proteins on the surface of the bacteria. Some vaccines are 
made with inactivated versions of these toxins. They are called ‘toxoids’ because they look 
like toxins but are not poisonous. They trigger a strong immune response. One example is 
tetanus: its symptoms are not caused by the Clostridium tetani bacterium, but by a 
neurotoxin it produces (tetanospasmin).131 
Immunizations for this type of pathogen can be made by inactivating the toxin that causes 
disease symptoms. As with organisms or viruses used in killed or inactivated vaccines, this can 
be done via treatment with a chemical such as formalin, or by using heat or other methods. 
Toxoids can actually be considered killed or inactivated vaccines, but are sometimes given 
their own category to highlight the fact that they contain an inactivated toxin, and not an 
inactivated form of bacteria. Toxoid vaccines are used to protect against diphtheria, and 
tetanus. 129, 130 
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2.3.2.4 Subunit vaccines 
Subunit vaccines do not contain any whole bacteria or viruses instead, these kind of vaccines 
contain polysaccharides (sugars) or proteins from the surface of bacteria or viruses.132 These 
polysaccharides or proteins are recognised by our immune system recognises ‘foreign’, and 
they are referred to as antigens. Even though the vaccine might only contain a few out of the 
thousands of polysaccharide/proteins in a bacterium, they are enough in themselves to 
trigger an immune response, which can protect against the disease. Subunit vaccines can be 
produced either by chemically degrading a pathogen and isolating its key antigens or by 
producing the antigens through genetic engineering. Because these vaccines contain only the 
essential antigens of a pathogen, the risk of side effects is relatively low. Because of their 
immunity and low production costs, they are viable alternatives to the traditional vaccines.103 
They can also be used on almost everyone who needs them, including people with weakened 
immune systems and long-term health problems. Subunit vaccines can be further categorized 
into following three categories: 
 
2.3.2.4.1 Protein based subunit vaccines 
Protein based subunit vaccines present an antigen to the immune system without viral 
particles, using a specific, isolated protein of the pathogen. Commonly used protein-based 
subunit vaccines are against acellular pertussis and Hepatitis B. A weakness of this technique 
is that isolated proteins, if denatured, may bind to different antibodies than the protein of 
the pathogen. 
 
2.3.2.4.2 Polysaccharide based subunit vaccines 
Polysaccharide vaccines are a unique type of inactivated subunit vaccine composed of long 
chains of sugar molecules that make up the surface capsule of certain bacteria. Pure 
polysaccharide vaccines are available for three diseases: pneumococcal disease, 
meningococcal disease, and Salmonella Typhi.  
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In 1983, PneumoVax (Merck and Co.), the first polysaccharide vaccine, was commercially 
launched.109 This vaccine was made up of unconjugated capsular polysaccharide isolated from 
14 serotypes of the Streptococcus pneumoniae bacterium, whereas the current version 
includes 23 out of approximately 90 known serotypes.110 In healthy adults, this vaccine 
induces good protection against most of the infections caused by these pathogens. 
Polysaccharide-based vaccines are poorly immunogenic, however, in infants, young children 
(under 2 years of age), the elderly, and immunocompromised patients, whereas in adults they 
induce only short-lasting antibody responses and fail to generate conventional B cell 
mediated immunological memory.  
The immune response to a pure polysaccharide vaccine is typically T-cell independent, which 
means that these vaccines are able to stimulate B cells without the assistance of T-helper 
cells.133 B cells directly recognize vaccine polysaccharides. No interaction occurs between Th 
and B cells (Figure 2.5A). T-cell independent antigens, including polysaccharide vaccines, are 
not consistently immunogenic in children younger than 2 years of age. Young children do not 
respond consistently to polysaccharide antigens, probably because of immaturity of the 
immune system.103, 133 
 
2.3.2.4.3 Conjugate subunit vaccines 
A conjugate vaccine is a type of subunit vaccine that consists of a protein conjugated to a 
capsule polysaccharide. Conjugate vaccines have been developed to enhance the efficacy of 
subunit vaccines against pathogens that have protective polysaccharide capsules that help 
them evade phagocytosis, causing invasive infections that can lead to meningitis and other 
serious conditions. Conjugate vaccines are made using a combination of two different 
components from the coats of bacteria. These coats are chemically linked to a carrier protein, 
and the combination is used as a vaccine. 
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Figure 2.5:  Depiction of T-cell-independent and T-cell-dependent responses to 
polysaccharide (A) and glycoconjugate vaccines (B). Adapted from J. Poolman et. al.134 
 
 
In the late 1980s, it was discovered that the chemical conjugation of polysaccharide with a 
protein molecule changes the immune response from T-cell independent to T-cell dependent, 
leading to increased immunogenicity in infants and antibody booster response to multiple 
doses of vaccine (Figure 2.5).135 Conjugate vaccines are used to create a more powerful, 
combined immune response as part of bacteria alone being presented would not generate a 
strong immune response on its own, while the carrier protein would. The piece of bacteria 
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can’t cause illness, but combined with a carrier protein, it can generate immunity against 
future infection.136 The vaccines currently in use for children against pneumococcal bacterial 
infections are made using this technique. In conjugate vaccines, B cells recognize the 
polysaccharide-protein conjugate of the vaccine. The protein carrier is processed and 
presented to T-helper (Th) cells in the context of the major histocompatibility complex (MHC), 
which induces T-cell activation. In turn, T cells stimulate the specific B cells to produce 
antibodies against the conjugate (Figure 2.5 B). The conjugate vaccines induce an antibody 
response of long duration. A key feature of conjugate vaccines is their ability to induce 
immunological prime in infants, with robust immune memory responses on subsequent 
booster vaccination with plain or conjugate polysaccharide. 
In 1931, Avery and Goebel suggested that the polysaccharide immunogenicity can be 
significantly enhanced by conjugation to an immunogenic carrier protein, and more recently 
successfully adopted to target some bacterial infections associated with high mortality 
rates.137 Glycoconjugate antigens are able to invoke T cell recruitment and immune B cell 
memory specifically directed toward the carbohydrate (Figure 2.5B).138 Glycoconjugate 
vaccines exert useful immunological activities, even in persons in high-risk groups, and their 
generation has been one of the greatest success stories in the biomedical sciences.139, 140 
Several conjugate versions of polysaccharide vaccines are now either commercially available 
or in development.141, 142 
The first conjugated polysaccharide vaccine was Hib. A conjugate vaccine for pneumococcal 
disease was licensed in 2000. A meningococcal conjugate vaccine was licensed in 2005.141 The 
development of cost-effective, glycoconjugate vaccines based on fully synthetic saccharide 
antigens is gaining growing importance, as demonstrated by the outstanding success of the 
synthetic vaccine QuimiHib® in Cuba in 2004.116  
 
 
2.4 Synthetic carbohydrates for Subunit vaccines 
The carbohydrate-based antigens are necessary for inclusion in a vaccine, however, there are 
several limitations associated with the use of isolated antigens. Naturally isolated 
carbohydrates are not readily available from natural sources and are available in very limited 
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quantity. Apart from their scarce availability, the isolation and purification of glycans from the 
natural sources is very challenging. The isolated glycans are heterogeneous and often 
contains impurities, which hampers with the vaccine efficiency. In particular, the 
heterogeneity of naturally occurring glycans, obtained by means of challenging isolation, 
purification and identification techniques, and bacterial impurities are the main limitations to 
further expansion in this field.143 Consequently, the development of future-generation 
vaccines is largely based on recourse to fully synthetic carbohydrate antigens with defined 
compositions, affording highly reproducible biological properties. Synthetic carbohydrate 
vaccines have important advantages over those isolated from natural sources because 
synthetic glycans can be produced as homogeneous compounds in a controlled manner with 
little or no batch-to-batch variability. The chain density and variables in chain length could be 
controlled and the optimized vaccine formulation can be obtained with fully synthetic 
glycans.103  
Synthesis, taking advantage of the glycosylation methods developed in the last decades,144, 
145 progress in automated synthesis,146-148 allows the construction of complex oligosaccharide 
fragments. The final product can be expected to have reliable structural integrity and 
appropriate purity for clinical application. Additionally, chemical modifications to the 
carbohydrate domain can be introduced during the optimization of the vaccine construct 
based on the requirement, an option often unavailable when the antigen has to be isolated 
from natural sources. Because of the danger of contaminating immunogens or disease-
causing microbes that can occur in vaccines derived from live cultures, fully synthetic antigens 
also possess better safety profiles. 
The synthetic approach which, starting from suitable monosaccharides, can provide pure and 
well-defined oligosaccharides for coupling to protein carriers, is increasingly attractive.149 
Improved synthetic protocols for oligosaccharide synthesis150-152, as well as the use of 
automated carbohydrate assembly, have provided more straightforward access to usable 
quantities of pure oligo saccharides. Synthetic carbohydrates have allowed the development 
of chemical approaches to glycomics that provide a molecular picture of biological processes 
involving carbohydrates. Synthetic sugars are beginning to be used in the development of 
diagnostic tests, vaccines and carbohydrate therapeutics.  
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2.5 Conclusion 
 
Over the last 50 years, GBS has remained a prominent concern for mother and neonatal 
health. Although universal screening and IAP have reduced the incidence of early-onset GBS 
sepsis, maternal and infant colonization rates remain unchanged, and IAP does not affect LOD 
and potential GBS-induced preterm birth. Despite the scientific advancements in the field of 
glycobiology, glycochemistry, and understanding of the immunology of pregnancy and early 
life, the neonatal mortality remains considerably. Although universal screening and IAP have 
reduced the incidence of early-onset GBS sepsis, maternal and infant colonization rates 
remain unchanged, and IAP does not affect LOD and potential GBS-induced preterm birth. 
Recent scientific discoveries in the molecular and microbial determinants of GBS vaginal 
colonization and placental disease have provided a better and clear understanding of host-
microbe interactions within the female reproductive tract. Furthermore, advances in GBS 
vaccines and human trials, as well as the emergence of novel targeted strategies to control 
GBS vaginal colonization, point to a new era beyond broad-spectrum antibiotics, and its 
detrimental consequences, to prevent neonatal GBS pathogenesis.  
Synthetic carbohydrate based conjugate vaccine present one of the most lucrative preventive 
strategy for neonatal GBS disease. In this regard, synthetic chemistry is a formidable tool to 
define the role of this crucial parameter, and each structural variable affecting the 
immunogenicity and efficacy of vaccine candidates. The rational design of carbohydrate 
antigens and the use of increasingly optimized synthetic strategies has made the synthesis of 
highly complex glycans possible. Nowadays, it is today possible to synthesize essentially any 
oligosaccharide or polysaccharide of interest. However, it may be very challenging, labourious 
and highly time consuming to attain the target molecule.  
In this regard this, thesis describes the efficient synthetic strategy for the synthesis of GBS 
type II oligosaccharide repeating unit. The aim is to develop a synthetic route that is easy to 
handle and efficient (economically as well as less time consuming with higher yield). 
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Chapter 3 
3 Group B Streptococcus (GBS) type II 
Oligosaccharide: Retrosynthetic 
analysis 
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3.1 Introduction 
Group B Streptococcus (GBS) is one of the leading causes of bacterial infections among 
neonates and pregnant women, resulting in many severe diseases such as sepsis, meningitis, 
abortion.1,2 Among the ten different serotypes according to their structurally distinctive 
capsular polysaccharides (CPSs),3, 4 type II GBS is associated with about 15% of the invasive 
infections in adults and infants.5, 6 GBS type II is one of the main GBS serotype responsible for 
neonatal infection and hence represents an important human pathogen. 
Rebecca Lancefield characterized the type-specific antigens of GBS type II in early 
immunological studies. 7-9 The type-specific antigens were polysaccharides and were 
originally extracted from whole organisms with hot hydrochloric acid. The extraction 
produced immunologically incomplete antigens, which form a lower molecular weight core 
to the complete native antigens.10-17 In 1966, Lancefield and Friemer found that the extraction 
of type II organisms using milder acidic conditions (trichloroacetic acid) yielded a more 
immunologically complete antigen.18 At that time, it was hypothesized that this was due to 
the presence of an acid-labile component in the original type II native polysaccharide, which 
was later identified as terminal sialic acid residue. 16, 18, 19 
Jennings et al.19 characterized the structure of type II GBS CPS in 1983. The native 
polysaccharide antigen isolated from type II group B Streptococcus contains D-galactose, D-
glucose, 2-acetamido-2-deoxy-D-glucosamine, D-sialic acid in the molar ratio of 3:2:1:1 
(Figure 3.1). The type II GBS polysaccharide is also structurally unique among other native 
GBS serotypes due to an additional terminal D-galactopyranosyl unit beside a terminal sialic 
acid residue. 
 
Figure 3.1: Structure of the heptasaccharide repeating unit of type II GBS capsular 
polysaccharide. 
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Although the antigenically critical terminal sialic acid residue unit present in all GBS serotypes 
(Figure 2.2), the terminal sialic acid residues of the native type II GBS antigen are also unique 
because they are not neuraminidase-sensitive and are connected directly to the backbone of 
the type II GBS antigen. While the terminal sialic acid residues of types Ia,12 Ib,14 and III15 
native GBS polysaccharides can be easily removed by treatment with bacterial 
neuraminidases, type II native GBS antigen are resistant to both viral and bacterial 
neuraminidases.19 The resistance to neuraminidases associated with the type II native antigen 
could be attributed to steric bulk as the sialic acid residues is attached directly to its backbone 
and interferes the approach of the enzyme. Another factor that probably affects the 
resistance is that the sialic acid is attached to O-3 position of a backbone β-D-galactopyranosyl 
unit, which also has a vicinal β-D-glucopyranosyl substituent at O-2 (Figure 2.2). 
Consequently, the vicinal linkages of these two sugar units to the same β-D-galactopyranosyl 
residue put them in very close proximity to each other. 
In this chapter, we discuss the structural features of GBS type II followed by the retrosynthetic 
analysis of GBS type II repeating unit to identify the suitable fragments used in our synthetic 
endeavour. 
 
 
3.2 Retrosynthesis of GBS II 
As characterized by Jennings et. al.,19 the structure of type II GBS CPS consists of a repeating 
heptasaccharide unit of GBS type II is composed of α-Neu5Ac (2-3)-ß-D-Gal-(1-4)- ß-D-GlcNAc-
(1-3)-[-ß-D-Gal-(1-6)]-ß-D-Gal-(1-4)-ß-D-Gal-(1-3)-ß-D-Glc. The chemical structure of GBS type 
II oligosaccharide repeating unit is shown in the Figure 3.2 as the corresponding 3-
aminopropyl glycoside. The glucose derived monosaccharide unit (Glc I and Glc II) has been 
presented in navy blue color; galactose based residues (Gal I, Gal II, and Gal III) in dark orange; 
N-acetylglucosamine unit (GlcNAc IV) in golden yellow; and terminal sialic acid unit (NeuNAc) 
in green in figure 3.2. It consists of a heptasaccharide repeating unit having pentasaccharide 
backbone ß-D-Gal-(1-4)-ß-D-GlcNAc-(1-3)-ß-D-Gal-(1-4)-ß-D-Gal-(1-3)-ß-D-Glc, and two 
decorating monosaccharide branches, an α-NeuNAc linked to the 3-O position of GalV and a 
ß-D-Gal linked to the 6-OH position of Gal III (Figure 3.2). 
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Figure 3.2: Chemical structure of the repeating unit of GBS type II capsular polysaccharide.  
 
 
 
Although the structure of GBS was resolved in 1983, the first chemical synthesis of GBS type 
II repeating unit was not reported until recently in 2018.20 The only reported synthesis of GBS 
type II has been achieved by following a conventional synthetic strategy where all the building 
blocks has been derived from a respective monosaccharide.  
The first step to develop an efficient synthetic strategy to achieve the GBS type II 
heptasaccharide repeating unit relies on a proper disconnection schemes. To transform the 
target molecule GBS II CPS repeating unit into simpler precursor molecules, a retrosynthetic 
analysis of the GBS II CPS repeating unit was done based on an intensive literature survey.  
The schematic representation of the retrosynthetic analysis of GBS type II is depicted Scheme 
3.1- suitable and appropriate protecting groups have been selected to obtain molecule 1, the 
partial protected form of GBS II CPS repeating unit.  
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Scheme 3.1: Retrosynthetic analysis of GBS type II repeating unit. 
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Partially protected heptasaccharide 1 could be achieved by enzymatic introduction of sialic 
acid residue to branched hexasaccharide 2. The branched hexasaccharide 2, obtained from 
fully protected branched hexasaccharide 3, could be obtained from glycosylation of linear 
chain pentasaccharide 4 and Gal I unit. This could be achieved by first selectively opening the 
benzylidene ring in the N-acetyl protected derivative of 4, followed by insertion of Gal I unit. 
The linear chain pentasaccharide 4 could be disconnected to yield protected lactosamine (Lac 
I) and trisaccharide 5. This could be performed by first deprotections of allyl group in 
trisaccharide 5 followed by glycosylation with protected lactosamine (Lac I). The trisaccharide 
5 could be obtained from the glycosylation of lactose based fragment (Lac II) and glucose 
based fragment (Glc I) based on the disconnection shown in Scheme 3.1. The retrosynthetic 
analysis of GBS II CPS repeating unit resulted in five building blocks (Lac I, Lac II, Glc I, Gal I, 
and Sialic acid) highlighted in the Scheme 3.1. 
The presented synthetic strategy is based on the five subcomponents derived from the retro 
synthetic analysis. Suitably protected lactosamine (Lac I) and lactose derivative (Lac II) are 
pivotal building blocks in our synthesis. 
 
 
3.3 State-of-the-art 
Although, the structure elucidation of GBS II CPS was done in 1983,19 the synthetic method 
to achieve the repeating unit of GBS II CPS was reported recently in April 2018 by Z. Guo and 
J. Gao et. al.20 However, the reported synthesis of GBS type II has been achieved by following 
a conventional synthetic strategy where all the building blocks derived from a respective 
monosaccharide units and the assembly of the heptasaccharide requires a high number of 
steps (each monosaccharide building blocks requiring 5-8 synthetic steps from the respective 
sugars) and relatively more number of glycosylation reactions (for combining all the 
fragments and to attach the linkers), which make it an overall challenging process. On the 
contrary, we have designed a different approach to achieve the chemical synthesis of GBS 
CPS II. In our synthetic endeavour, we have used five subcomponents based on our 
retrosynthetic analysis. Suitably protected lactosamine and lactose derivatives are pivotal 
building blocks in our synthesis and both disaccharide fragments has been obtained from the 
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cheap and readily available lactose, produced in huge amounts as a side product in dairy 
industry.  
 
 
 
 
Figure 3.3: The building blocks for the synthesis of the repeating unit of GBS type II capsular 
polysaccharide reported by Z. Guo et. al. (to the left) and our synthetic approach (to the right). 
 
 
 
The building blocks in the reported synthetic strategy and in our synthetic method have been 
presented in Figure 3.3. The key advantages of the presented synthetic strategy in the thesis 
are summarized here: 
 
 
 Number of synthetic steps: 
Since we are proposing the total synthesis of GBS II CPS repeating unit from five building 
blocks, comprising two disaccharide-derived building blocks, the total number of steps in the 
synthesis of proposed building blocks in our synthetic strategy are less than that in the 
strategy with all monosaccharide sub components. This will make the synthesis less time 
consuming.  
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 Number of glycosylation reactions: 
The chemical glycosylation is a challenging process due to the necessity to control the desired 
stereoselectivity. Therefore, an inferior number of fragments (two disaccharide fragments) 
reduces the number of glycosylation reaction in the synthetic strategy and make the overall 
approach relatively less complex. 
 
 
 Enzymatic introduction of Sialic acid residue: 
The introduction of sialic acid in our approach is planned to be performed enzymatically, using 
specific sialyltransferase enzymes, to the partially protected branched hexasaccharide at 
University of Manchester with Glycovax partner Professor Sabine Flitsch. The use of 
sialyltransferase enzymes in our synthesis will provide advantage in selectivity and yield 
compared to the chemical glycosylation. 
 
 
 Economically efficient 
Two of our backbone building blocks are derived from readily available and very cheap 
starting material lactose.  
 
To conclude, the presented strategy provides and efficient, easy-handling, economically 
efficient synthetic route towards GBS II CPS repeating unit. 
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Chapter 4 
4 Synthesis of GBS CPS II 
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This chapter consists of the synthetic strategy to achieve all the fragments derived from the 
retrosynthetic disconnections of GBS II CPS repeating unit, described in Chapter 3. Synthetic 
strategy to obtain the proposed fragments was optimized to produce the desired molecules 
in an efficient manner with the aim to reduce the complexity of the method as well as to get 
the sub-components in a decent yield. The strategy starts with the most challenging fragment 
so that the least difficult steps are carried out on more complex substrates at a later stage. 
Henceforth, the proposed fragment will be denoted as compounds 46, 24, 31, 38, and 45 as 
shown in Figure 4.1 in different colours and separate boxes. 
 
  
Figure 4.1: Building blocks for the synthesis of GBS II CPS oligosaccharide repeating unit. 
 
 
This chapter describes the synthetic strategy to achieve the building blocks 17, 24, 31, and 38 
in good yields under optimized conditions.  
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4.1 Synthesis of Building block 17 
Building block 17 is the glucose-derived fragment with the azide ending linker as shown in 
Figure 4.1 in pink color. Compound 17 contains benzyl-protecting group at 2, 4, and 6-O 
position and orthogonal allyl protection at 3-OH. Two synthetic methods were explored to 
obtain compound 46.  
 
 
4.1.1 Synthesis of Building block 17: method I 
Synthesis of compound 17 was first approached by following the method described in Scheme 
4.1.1, 2 Peracetylated glucose was used as a starting material. 
 
 
 
Scheme 4.1: Synthetic strategy to obtain compound 12 as a building block .1,2 
 
 
First, the glycosylation of acetyl protected glucose using thiophenol as the acceptor and 
BF3OEt2 as the activator followed by deprotections of the remaining acetyl groups led to 
compound 7. Then the benzylidene ring formation at 4- and 6-position using benzaldehyde 
dimethyl acetal and para-toluenesulfonic acid (p-TsOH) to result compound 8, followed by 
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the regioselective tert-butyldimethylsilyl (TBS) protection at 3-OH with TBSCl in the presence 
of imidazole to yield molecule 9. The benzoyl (Bz) protection of the free OH group at position 
3- followed by the attachment of azidopropyl linker (prepared by reacting 3-bromopropanol 
with sodium azide and Zn)2 using trifluoromethanesulfonic (TfOH) and N-iodosuccinimide 
afforded compound 11. Up to compound 11, the synthetic strategy worked well but when 
attempted the hydrolysis of the benzylidene ring with camphorsulfonic acid (CSA), the 
migration of TBS group was observed and the reaction provided the complex inseparable 
mixture of products. This complication affected the yield in a negative way and made the 
approach more challenging due to tough purification. Therefore, an alternative approach to 
obtain building block 17 was explored to overcome this limitation and obtain the desired 
molecule in a more efficient manner. 
 
 
4.1.2 Synthesis of building block 17: method II 
In our new approach to molecule 17, peracetylated glucose was again used as a starting 
material. Building block 17 was prepared by glycosylation of per acetylated glycose using 3-
chloro-1-propanol as the acceptor and BF3OEt2 as the activator (Scheme 4.2).3, 4 Then, the 
alkyl chloride 12 was treated with sodium azide in DMF at 80 °C to introduce the azido group 
and afford compound 13.  
 
 
Scheme 4.2: Synthetic approach to obtain compound 17. 3, 4 
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Deacetylation of glycosides 13 under with K2CO3 yielded the desired azidoglycoside 14 
followed by the benzylidene ring formation on 4- and 6-position using benzaldehyde dimethyl 
acetal in the presence of para-toluenesulfonic acid (p-TsOH) to give compound 15. Compound 
15 was then treated with dibutyltin oxide (Bu2SnO), cesium fluoride (CsF) and allyl bromide 
(AllylBr) to perform the selective allylation on position 3 to get alcohol 16. Finally, the 
benzylidene acetal hydrolysis, followed by benzylation of the remaining free OH groups 
afforded building block 17 and the removal of the allyl ether afforded accepter 46 for 
glycosylation. (Scheme 4.2). Altogether, compound 17 was obtained in 35% overall yield over 
9 steps. 
 
 
4.2 Synthesis of Building block 24 
Lactose, an abundant natural disaccharide, is the first and only carbohydrate every newborn 
mammal consumes in significant amounts. Lactose is composed of galactose and glucose 
monosaccharides linked with a β(-1→4) glycosidic linkage. Lactose comprises about 2-8 % of 
mammal’s milk by weight where it is the principal carbohydrate and energy source.5 Lactose 
production in nature is limited to the mammalian breast, which contains the enzyme system 
(lactose synthase) necessary to create β(-1→4) glycosidic linkage.6 In addition, lactose is a 
cheap readily available side product in dairy industry, since several million tons of lactose are 
produced annually. Lactose, being water soluble, is associated with the whey portion of dairy 
foods.  
On that basis lactose was used as a starting material to achieve building block 24 and building 
block 31 in our synthetic strategy. Synthesis of building block 24 was achieved using the 
method described in Scheme 4.3. 7 The acetyl protection of all free OH groups was carried 
out by using acetic anhydride in the presence of iodine, followed by the regioselective 
removal of 1-O-acetyl group with hydrazinium acetate to give compound 19. Then 1-O-
silylation with TBSCl in the presence of imidazole afforded silyl β lactoside followed by 
removal of all O-acetyl groups under Zemplen condition (sodium methoxide/methanol) to 
provide compound 21. However, several complications arose in these steps. First, the 1-O-
silylation occurred with poor stereoselectivity and afforded α/β mixture of the silyllactoside. 
- 69 - 
 
In addition, partial 1-OH and 2-OH silyl group migration was observed during the deprotection 
of the acetyl groups sodium methoxide, as depicted in the mechanism shown in scheme 4.4.8 
 
 
Scheme 4.3: Synthetic scheme to achieve building block 24.8 
 
 
Both anomerization and silyl migration caused problems when the subsequent steps were 
performed using the unseparated mixture of compounds. The issue of silyl migration could 
be addressed by lowering the reaction temperature to -15 °C, enabling to obtain the anomeric 
mixture of the silyllactoside in 91% yield (Scheme 4.4). The pure α-form of compound 21 was 
achieved by crystallization in ethylacetate/methanol (1:1) to reduce the complications in the 
next steps  
Further, the regioselective allylation of pure α-form of compound 21 could be accomplished 
with Bu2SnO/ toluene, and allyl bromide, Bu4NI in THF to yield intermediate 22. This 
compound was protected at C4, C6-OH position with a benzylidene acetal to yield 23. The 
acetylation of the remaining hydroxyls of molecule 23 was performed by using anhydrous 
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pyridine and acetic anhydride with a catalytic amount of DMAP to give compound building 
block 24. 
 
 
Scheme 4.4: Mechanism of action for 1, 2 -O-silyl group migration.8 
 
According to scheme 4.3, the lactose-based building block 24 was obtained in 33% overall 
yield over 7 steps. 
 
 
4.3 Synthesis of Building block 31 
Lactosamine is one of the most important building blocks of biologically relevant 
oligosaccharides and is a basic structural element of Lewis type, α-Gal type, and human milk 
oligosaccharides.9 Lactosamine forms the backbone of several cell surface glycans such as 
sialylated glycans or keratin sulfates.9 Oligo-N-acetyllactosamine and poly-N-
acetyllactosamine are ubiquitous components of N- and O-glycans decorating the surface of 
mammalian cells. These structures are natural ligands for proteins of the galectin family with 
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the binding interaction modulating cell-cell adhesion, inflammatory and immune responses, 
and a variety of disease-associated processes, e.g., tumour development and metastasis.10 
Therefore, a facile synthesis of the lactosamine building block serving as a universal building 
block would be of great importance in the assembly of the abovementioned glycans.  
Due to its structural and biological importance, several enzymatic and chemical syntheses 
have been developed for the preparation of lactosamine and derivatives. The enzymatic 
synthesis is usually based on the transfer of a galactose unit onto glucosamine by glycosyl 
hydrolase or transferase enzyme.11 The conventional strategy for synthesis of the lactosamine 
building block involves the glycosylation of a suitably protected glucosamine acceptor with a 
galactose donor; however, this is very tedious and time consuming.12 Another strategy is to 
convert commonly available lactose into lactosamine via functionalizing the lactal via 
iodosulfonamidation, but this approach is similarly labourious as the previous one.13 In this 
regard, a lengthy and labourious synthetic route is necessary to obtain the required specific 
linkage both in terms of regioselectivity and anomeric stereoselectivity, and the installation 
of orthogonal protecting groups (e.g., 5-6 steps for the synthesis of each building block). Stutz 
and co-workers have applied the Heyns rearrangement to convert lactulose into a 
lactosamine.14 
 
 
Scheme 4.5: Synthetic strategy for building block 31 via Heyns rearrangement.15 
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In our approach, we first tried to obtain building block 31 via Heyns rearrangement, but as we 
were working on a small scale, the one pot synthetic method (Scheme 4.5) provided a 
complex mixture of products that made the purification process very complicated. Therefore, 
we decided to adopt a different approach to obtain building block 31.  
 
 
Scheme 4.6: Synthetic strategy for compound 30 from lactose.17 
 
 
Accordingly, a robust and easy-handling method to achieve suitably protected lactosamine 
building block from inexpensive lactose was investigated by following the work of Lafont and 
co-workers to obtain N-acetyl lactosamine from lactose.16 The synthetic scheme is described 
in Scheme 4.6. First the complete acetyl protection of lactose was performed with acetic 
anhydride to give the octaacetate, which was then treated with HBr (25% in AcOH) to give the 
anomeric bromide. The reaction was quenched by the addition of sodium acetate, and the 
mixture was poured into a suspension of zinc (Zn) in AcOH in the presence of CuSO4 to afford 
the lactal 25 in high overall yield. Next, iodoacetoxylation of hexa-acetylated lactal 25 was 
achieved by addition of a slight excess of iodine in the presence of cupric acetate 
monohydrate in acetic acid at 80 °C. The reaction showed high stereoselectivity, affording 26 
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in high yield. Then the glycosylation with trimethylsilyl azide afforded compound 27 with 
excellent stereoselectivity, followed by the Staudinger reaction with triphenylphosphine. The 
Staudinger reaction led to situ formation of iminophosphorane, followed by rearrangement 
with the elimination of iodine at C-2 position. The resulting aziridine intermediate reacted 
with ethane thiol and triphenyl phosphine to afford the corresponding 2-aminophosphonium 
iodide lactosamine ethylthio β-glycoside 28, the Lafont intermediate. This compound 
appeared to be very stable and could be isolated and purified by silica gel column 
chromatography. To convert compound 28 into its free-amino group derivative, the Lafont 
intermediate was reacted with salicylaldehyde in presence of triethylamine under 
microwaves to form imine 29, which could then be easily converted into the free-amino 
derivative 30 with aq. 3M HCl solution (Scheme 4.6) in 76% yield.  
 
 
Scheme 4.7: Synthetic of lactosamine glycosyl donors 31, and 32. 
 
 
A key point to note is the choice of N-protecting group on the glucosamine since it should be 
capable of providing neighbouring group participation to ensure high β-selectivity in the 
subsequent glycosylation reaction, and stable under both enzymatic and chemical reaction 
conditions.18 A survey of different N-protecting groups led us to trichloroethoxycarbonyl 
(Troc) group. Troc is a suitable protecting group because it can be easily introduced and 
removed, and is able to promote β-selective glycosilations via anchimeric assistance. 
Additionally, the reactivity of donors with a C-2 N-Troc group is higher compared with the 
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corresponding N-phthalimido-protected donors. Furthermore, the N-Troc group is stable 
under various standard conditions used for chemical and enzymatic oligosaccharide 
synthesis, although it is sensitive to alcoholysis under basic conditions. 
To synthesize a suitable lactosamine glycosyl donor from free amino sugar 30, and to further 
exemplify the efficiency of the method, compound 30 was protected with the commonly used 
protecting groups (Scheme 4.7); Phth (with Phthalic anhydride), and Troc (with 2,2,2-
Trichloroethoxycarbonyl chloride). Troc protected lactosamine donor 31 was obtained in 
good yield (77%) by reaction with TrocCl in the presence of triethylamine, while the 
protection with phthalic anhydride provided the thioglycoside 32 in poor yield (10%).  
The synthetic method paves the way to a rapid and robust synthesis of a suitably protected 
lactosamine building block from inexpensive starting material such as lactose via the Lafont 
intermediate. The stable 2-aminophosphonium iodide lactosamine glycoside has previously 
been shown not to be amenable to transformation into a useful glycosyl building block. 
However, as shown by X. Li et. al., it could be converted to imine derivative on reaction with 
salicylaldehyde under microwave conditions which upon mild acid hydrolysis gave rise to the 
2-amino lactosamine.17 The described approach could also be implemented to convert other 
types of sugars to form the corresponding 2-aminosaccharides. 
 
 
4.4 Synthesis of Fragment 38 
 
Fragment 38, required as a glycosyl donor, was synthesised in good yield from peracetylated 
galactose via ortho ester 34 in six steps (Scheme 4.8) following a commonly used synthetic 
approach.19, 20 Acetylated galactose was first treated with HBr solution in acetic acid in dry 
DCM to provide glycosyl bromide 33. The ortho ester 34 was prepared by heating 33 in 
anhydrous DCM in the presence of sym-collidine, anhydrous methanol and tetra-n-
butylammonium bromide (TBAB). The acetyl groups were then removed with sodium 
methoxide and the resulting free hydroxy groups were benzylated to give ortho ester 36 in 
good yield.  
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Scheme 4.8: Synthetic approach to achieve building block 38. 
 
 
The ortho ester group was partially removed by treatment with p-toluenesulfonic acid (PTSA) 
in acetone/water mixture, and the resulting 2-O-acetylated compound 37 was then activated 
using 2,2,2-trifluoro-N-phenylacetimidoyl chloride using cesium chloride in DCM to yield 
building block 38. The compound 38 was obtained easily in good 30% overall yield in 6 steps. 
 
 
4.5 Combining of building blocks 
 
After achieving the synthesis of core building blocks, the fragments were combined as 
described in the retrosynthetic analysis to obtain the target compound GBS II CPS. 
 
 
4.5.1 Synthesis of trisaccharide 5- (2+1 glycosylation) 
The first assembly step was a 2+1 glycosylation using lactose-based building block 24 as a 
donor and activated compound 46 as an accepter. First the activation of lactose donor 24 was 
performed by deprotection of the TBS group followed by activation of the anomeric hydroxyl 
with 2,2,2-trifluoro-N-phenylacetimidoyl chloride and cesium chloride in DCM. 
Disappointingly, when the silyl deprotection was performed at room temperature using tetra-
n-butylammonium fluoride (TBAF), the reaction provided both the TBS deprotected 
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disaccharide hemiacetal 39 and the acyl migrated sugar 40. To avoid the acyl migration, the 
reaction was carried out at -10 °C and the compound 39 was achieved exclusively (Scheme 
4.9). 
 
 
Scheme 4.9: Activation of lactose glycosyl donor. 
 
 
 
Lactose donor 41 was then reacted with glucose acceptor 46 at 0 °C in DCM and in the 
presence of TMSOTf as promoter to give trisaccharide 5 in 80% yield (Scheme 4.10). The 
stereochemistry of the new glycosidic bond of trisaccharide 5 was confirmed by 1H NMR 
spectrometry by proton-proton coupling constant. 
 
 
Scheme 4.10: (2+1) glycosylation to provide trisaccharide 5. 
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The trisaccharide 5 was fully characterized by nuclear magnetic resonance (NMR) 
spectroscopy and high-resolution mass spectrometry (HRMS). The full characterization was 
performed using 2-D 1H-1H correlation spectroscopy (COSY) and 1H-13C heteronuclear single-
quantum correlation spectroscopy (HSQC). 
 
 
4.5.2 Synthesis of linear chain pentasaccharide 4 - (3+2 glycosylation) 
Next, the synthesis of linear chain pentasaccharide 4 was performed. Troc-protected 
lactosamine 31 was used as a donor and allyl deprotected trisaccharide 42 as an acceptor 
with NIS and TfOH as promoters in the glycosylation reaction (Scheme 4.11). The allyl 
deprotection of compound 5 was carried out in two steps. First, allyl to propenyl ether 
isomerization catalysed by (1,5-Cyclooctadiene)bis(methyldiphenylphosphine)iridium(I) 
hexafluorophosphate (iridium complex) followed by the vinyl ether hydrolysis using I2 in a 
THF/water mixture.3 The structure of compound 42 was confirmed by 1-D NMR, COSY NMR, 
HSQC NMR, and mass spectroscopy. 
 
 
Scheme 4.11: (3+2) Glycosylation to obtain linear chain pentasaccharide 4. 
 
 
 
Various promoters such as TESOTf (trimethylsilyl trifluoromethanesulfonate), TMSOTf 
(Trimethylsilyl trifluoromethanesulfonate), and TfOH (Triflic acid) were explored to optimize 
the reaction conditions and to obtain compound 4 in good yield (Table 4.1). The use of TfOH 
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as an acid promoter in DCM at -20 °C provided the linear chain pentasaccharide in high yield 
(80%). 
 
Entry Donor 
(equiv) 
Acceptor 
(equiv) 
Promoter 
(equiv.) 
NIS 
(equiv) 
Solvent Temp 
(0C) 
Yield 
1 1.05 1.0 TESOTf 
(0.8) 
2.1 Et2O 0  - rt 20 -30 % 
2 1.1 1.0 TMSOTf 
(0.8) 
2.1 DCM 0  - rt 20-30 % 
3 1.3 1.0 TfOH 
(0.7) 
1.2 Et2O -20 - 0 20-30 % 
4 1.2 1.0 TfOH 
(0.4) 
1.4 DCM -20 80 % 
Table 4.1: Optimization of (3+2) glycosylation in scheme 4.11. 
 
 
The formation of pentasaccharide 4 was confirmed by mass spectroscopy and 1H NMR 
spectroscopy. The mass spectroscopy and elemental composition report confirms the 
structure. The characterization was also performed by 2-D total correlation spectroscopy 
(TOCSY) and 1H-13C HSQC NMR correlation spectroscopy. The presence of five anomeric 
carbons in 13C NMR spectrum confirms the formation of pentasaccharide 4. The obtained 
pentasaccharide 4 was fully deprotected according to scheme 4.12. First, the Troc group was 
removed from the glucosamine unit using 1M TBAF solution in THF, followed by N-acetylation 
to yield compound 43.21 Partially deprotected pentasaccharide 43 was analysed with NMR 
and mass spectroscopy and is in good agreement with the structure. (See experimental 
section) 
Compound 43 was then fully deprotected over two steps using sodium methoxide (for 
deacetylation) and final hydrogenation with palladium hydroxide as catalyst to afford 
pentasaccharide 44. The fully deprotected pentasaccharide 44 was characterized by NMR 
spectroscopy. The low-resolution mass analysis confirms the formation of fully deprotected 
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pentasaccharide however; the full structural characterization including the purity and 
glycosidic linkages is still ongoing. 
 
 
 
Scheme 4.12: Fully deprotected linear chain pentasaccharide 4. 
 
 
 
As far as the synthesis of the hexasaccharide, precursor of the acceptor for enzymatic 
sialylation, the final steps are currently ongoing. They includes the reductive opening of the 
benzylidene acetal of pentasaccharide 43 to deliver the 6-OH, followed by the glycosylation 
with donor 38 (Scheme 4.13). 
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Scheme 4.13: Scheme to obtain hexasaccharide 3. 
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4.6 Results Summary 
The results obtained so far are summarized in table 4.2. 
Molecule Structure Results 
46 
 
Completed in 
35% overall 
yield 
over 9 steps 
 
24 
 
 
Completed in 
33% overall 
yield 
over 7 steps 
from lactose 
 
31 
 
Completed in 
33% overall 
yield 
over 7 steps 
from lactose 
 
38 
 
Obtained in 
overall 30% 
yield over 5 
steps 
 
5 
 
Obtained in 80 
% yield 
 
4 
 
Obtained in 80 
% yield 
 
Table 4.2: Summary of the results obtained in the synthesis of GBS type II CPS repeating 
unit. 
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4.7 Conclusions and perspectives 
To conclude, this thesis work presents an efficient and easy handling synthetic approach to 
the heptasaccharide repeating unit of GBS type II. The presented strategy has been developed 
to make the synthetic procedure more expeditious in comparison to the one previously 
reported. The use of readily available and cheap dairy side-product lactose for the synthesis 
of two key building blocks B and C is an added value to our strategy, allowing the synthesis of 
the pentasaccharide backbone of the target compound. Since we employed lactose as a 
common precursor of two disaccharide intermediates, our methods allows to reduce the 
number of challenging glycosylation reactions. The results summarized in Table 4.2 shows the 
efficiency of the developed synthetic approach.  
The final steps of the synthesis comprise- the incorporation of building block 38 into the linear 
chain pentasaccharide (currently ongoing) followed by the enzymatic introduction of sialic 
acid. The sialic acid unit (NeuNAc fragment) will be incorporated enzymatically at the 
University of Manchester in the group of Professor Sabine Flitsch, a partner of the Glycovax 
network, during my upcoming secondment. Following the enzymatic introduction of the sialic 
acid unit, the obtained partially protected heptasaccharide will subsequently be fully 
deprotected to yield the repeating unit of GBS type II capsular polysaccharide.  
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Chapter 5 
5 Experimental Section 
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5.1 General experimental methods 
 
 
5.1.1 Thin Layer Chromatography (TLC) 
Thin Layer Chromatography (TLC) and High Performance Thin Layer Chromatography (HPTLC) 
were performed on Merck precoated 60F254 plates (0.25 mm and 0.2 mm thickness, 
respectively). Reactions were always monitored by TLC analysis. Compounds were visualized, 
when appropriate by UV light (254 nm), and always by staining with the solutions given below 
and detected by heating at 196°C  The solution used as stains are: 
 
- molybdic solution (21 g of (NH4)4Mo4O24, 1 g of Ce(SO4)2, 31 mL of H2SO4 98%, 970 mL H2O) 
- sulphuric acid (50 mL of H2SO4 98%, 450 mL of MeOH, 450 mL H2O) 
- ninhydrin (2.7 g of 2,2-dihydroxyindane-1,3-dione, 27 mL of AcOH, 900 mL of EtOH) 
 
 
5.1.2 Flash chromatography 
According to Still procedure,1 compounds were purified by flash chromatography, using Silica 
gel (SiO2, high-purity grade (Merck Grade 9385), pore size 60 Å, 230- 400 mesh particle size) 
from Sigma-Aldrich. In some cases it was also used a flash purification system, Biotage SP1. 
Normal- and reverse phase Biotage SNAP cartridges (sizes from 10 g to 340 g, standard 50 μm 
silica) were used to purify the compounds. 
 
5.1.3 Nuclear Magnetic Resonance (NMR) analysis 
NMR spectra were recorded on a Bruker AMX 400 instrument (400 and 100.6 MHz for 1H and 
13C, respectively), and were all run at room temperature (298K), unless otherwise noted. The 
samples were prepared using deuterated solvents (CDCl3, D2O and CD3OD from Sigma-
Aldrich). Chemical shifts (δ) are reported in ppm and the coupling constants (J) in Hz. Chemical 
shifts were referenced to the residual proton in the solvent (e.g. the CHCl3, 0.01 % in 99.99 % 
CDCl3), according to Gottlieb and Nudelman.2 Multiplicities are abbreviated as: br (broad), s 
(singlet), d (doublet), t (triplet), hept (heptet), m (multiplet) or combinations thereof. 1H-NMR 
spectra were recorded for all the synthesized products. In the case of unknown structure, the 
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characterization is reported by 1H-NMR and 13C-NMR. 2-dimensional NMR experiments 
(COSY, TOCSY, HSQC and HMBC) were used to better assign peaks to the structure. 
 
 
5.1.4 Mass analysis 
Low resolution mass analyses were recorded in negative or positive mode on a Thermo 
Finnigan LCQ Advantage equipped with an ESI source. High-resolution mass analyses were 
recorded on a Waters Micromass Q-Tof micro equipped with a LockSpray ESI source or on a 
Bruker Daltonics ICR-FTMS APEX II at C.I.G.A, University of Milan.  
 
 
5.1.5 Anhydrous environment 
Unless otherwise stated, all the reaction were conducted under nitrogen atmosphere. When 
stirred overnight, the reaction were put under anhydrous atmosphere by an Argon-balloon. 
Solvents Unless otherwise stated, all the reactions were performed using dry solvents. DCM, 
Et2O, MeOH, pyridine, toluene, DMF, CH3CN and THF over molecular sieves were purchased 
from Sigma-Aldrich and used without further purifications. 
 
 
 
 
 
 
 
 
 
 
 
 
- 88 - 
 
5.2 Synthetic Procedures 
 
 
5.2.1 Synthesis of Building block 17 
 
 
 
Synthesis of 3-chloropropyl 2,3,4,6-tetra-O-acetyl-β-D-glucopyranoside (12)3: To a stirred 
solution of pentaacetylated glucose (8.0 g, 20.5 mmol) and 3-chloro-1- propanol (3.7 mL, 41.0 
mmol) in anhydrous DCM (50 mL), BF3.Et2O (5 mL, 41.0 mmol) was added dropwise at 0 °C. 
The reaction mixture was allowed to warm up to room temperature and then stirred for 18 
hours. After the completion of the reaction, the reaction mixture was poured into ice water 
and stirring was continued until the ice had melted. After phase separation, the water layer 
was extracted with DCM (3x 100 mL) and the combined organic phase were washed with aq 
NaHCO3 solution (100 mL), and 100mL brine solution. The organic phase was then dried over 
MgSO4 and the solvent was evaporated in vacuo to yield the product as yellow viscous oil in 
50 % yield (4.4 g). TLC- 6:4 (hexane:ethyl acetate). The product was used for further reaction 
without purification. Spectroscopic data were in agreement with those reported in the 
literature.3 
 
 
 
 
Synthesis of 3-azidopropyl 2,3,4,6-tetra-O-acetyl-β-D-glucopyranoside (13)3: To the solution 
of 12 (8.0 g, 17.1 mmol) in dry DMF (50 mL), sodium azide (5.6 g, 85.4 mmol) was added. The 
resulting solution was stirred at 60 °C overnight and then the DMF was removed under 
reduced pressure. The reaction mixture was then diluted with DCM (120 mL) and the organic 
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phase was washed with water (100 mL) and aq. sodium bicarbonate solution. The organic 
phase was then dried over sodium sulphate and concentrated on rotary evaporator. The 
crude product was purified using column chromatography with hexane: ethyl acetate (2:1) as 
eluent and obtained compound 13 in quantitative yield (3.9 g). Spectroscopic data were in 
agreement with those reported in the literature.3  
 
 
 
 
Synthesis of 3-azidopropyl β-D-glucopyranoside (14)3: Anhydrous potassium carbonate (0.13 
g, 0.9 mmol) was added to solution of compound 13 (3.8 g, 9.0 mmol) in dry methanol (30 
mL). The reaction mixture was then stirred overnight at room temperature. After completion 
of the reaction as indicated by TLC (15% MeOH in CHCl3). The mixture was concentrated and 
compound was purified by silica gel column chromatography and eluted with 12% MeOH in 
CHCl3 to give a viscous liquid: yield 95%, 2.2 g. Spectroscopic data were in agreement with 
those reported in the literature.3 
 
 
 
 
Synthesis of 3-azidopropyl 4,6-O-benzylidene-β-D-glucopyranoside (15)3: To a solution of 14 
(1.9 g, 7.0 mmol) in MeCN (30 mL) was added benzaldehyde dimethylacetal (1.6 mL, 10.6 
mmol) and p-TsOH (0.02 g, 0.1 mmol).The solution was stirred for 1 hour at room temperature 
and then the reaction was quenched with triethyl amine. The solution was then evaporated 
to dryness and purified with silica get column chromatography with hexane: ethyl acetate 
(1:2) and obtained in 80 % (2.0 g) yield as a white solid: Rf = 0.5. 1H NMR (400 MHz, 
Chloroform-d) δ 7.41-7.35 (2 H, m), 7.29-7.21 (3 H, m), 5.41 (1 H, s), 5.30 (1 H, s), 4.29 – 4.18 
(2 H, m), 3.85 (1 H, dt, J 10.0, 6.1), 3.73 – 3.62 (1 H, m), 3.57 (1 H, dt, J 10.0, 6.1), 3.46 – 3.28 
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(3 H, m), 3.24 (3 H, s), 3.15 (1 H, s), 1.83 – 1.74 (2 H, m); 13C NMR (101 MHz, Chloroform-d) δ 
137.1, 129.4, 128.5, 128.4, 128.3, 126.8, 126.4, 103.3, 102.0, 80.6, 77.5, 77.2, 76.8, 74.6, 73.3, 
68.7, 67.2, 66.5, 52.8, 48.4, 29.2. 
 
 
 
 
Synthesis of 3-azidopropyl 3-O-allyl-4,6-O-benzylidene-β-D-glucopyranoside (16)4: A 
mixture of compound 15 (2.0 g, 5.9 mmol) and Bu2SnO (2.9 g, 11.8 mmol) in toluene (70 mL) 
was refluxed under N2 overnight. The reaction was then cooled down to room temperature 
and toluene was removed under reduced pressure. Then the resulting residue was dissolved 
to dry DMF (30 mL) and mixed with CsF (2.6 g, 17.7 mmol) followed by the addition of 
allylbromide (765.3 µL, 8.8 mmol). The solution was stirred at room temperature for 24 hours 
and after completion of the reaction, the solution was diluted by ethylacetate (200 mL) and 
washed with saturated aq. NaCl solution (100 mL). The organic layer dried over Na2SO4 and 
concentrated under reduced pressure. The purification of the residue by flash column 
chromatography with ethyl acetate/hexane (1:3) as eluent yielded the desired compound in 
52 % yield (1.2 g) as white foam. Spectroscopic data were in agreement with those reported 
in the literature.4 
 
 
 
 
Synthesis of 3-azidopropyl 3-O-allyl-2,4,6-O-benzoyl-β-D-glucopyranoside (17)4: The 
compound 16 (1.0 g, 2.5 mmol) in 10% TFA in CH2Cl2 (20 mL) and H2O (2 mL) was stirred at 
room temperature for 2 h and progress of the reaction was monitored using TLC. On 
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completion of the reaction, as indicated by TLC, the mixture was co-evaporated with toluene 
under vacuum to provide a residue.  
To a solution of this obtained residue in 20 mL of anhydrous DMF was added NaH (0.5 g, 13.3 
mmol) and BnBr (1.3 mL, 10.6 mmol) at 0 ℃ under a N2 atmosphere. After an hour, MeOH 
was added slowly to quench sodium hydride the reaction followed by the addition of H2O. 
The aqueous phase was extracted with EtOAc (3 × 100 mL), and the combined organic layer 
was dried over Na2SO4 and concentrated under reduced pressure. The residue was purified 
by a flash silica gel column chromatography with EtOAc/ hexanes (1:11) as the eluents to give 
colourless syrup in 70 % (1.0 g) yield over 2 steps. Spectroscopic data were in agreement with 
those reported in the literature.4 
 
 
 
 
Synthesis of 3-azidopropyl 2,4,6-O-benzoyl-β-D-glucopyranoside (46): Building block 17 
(0.60 g, 1.1 mmol) was dried and reaction flask was evacuated. Iridium catalyst was added to 
the flask following the evacuation of the flask. THF was then added to the flask and the 
reaction mixture was stirred at room temperature. A balloon of H2 gas was attached and this 
reaction was monitored until the red color of the solution turned to pale yellow. H2 balloon 
was then removed and the flask was flushed with Argon gas and stirred for another 6 hours. 
The resulting solution was concentrated and dissolved in 80% THF in water (5 mL) followed 
by the addition of I2. The resulting solution was stirred at room temperature for an hour, 
quenched by addition of saturated sodium thiosulfate solution, and washed with sodium 
bicarbonate, brine and water. Concentrated and evaporated then separated by Flash 
Chromatography to afford 46 in 70% yield over 2 steps. 1H NMR (400 MHz, Chloroform-d) δ 
7.39 – 7.23 (13 H, m), 4.93 (1 H, d, J 11.5), 4.84 (1 H, d, J 11.2), 4.68 (1 H, d, J 11.5), 4.63 (1 H, 
d, J 12.2), 4.60 – 4.53 (2 H, m), 4.38 (1 H, d, J 7.8), 4.04 – 3.97 (1 H, m), 3.78 – 3.69 (3 H, m), 
3.69 – 3.61 (1 H, m), 3.56 – 3.49 (1 H, m), 3.47 (1 H, d, J 6.2), 3.42 (2 H, t, J 6.8), 3.28 (1 H, dd, 
J 9.1, 7.8), 2.44 (1 H, s), 2.01 – 1.82 (2 H, m), 1.59 (1 H, s); 13C NMR (101 MHz, Chloroform-d) 
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δ 138.3, 138.2, 128.6, 128.4, 128.4, 128.0, 127.8, 127.7, 103.2, 81.4, 77.4, 77.4, 77.0, 76.7, 
74.8, 74.5, 73.5, 68.9, 66.5, 48.4, 29.3. 
5.2.2 Synthesis of Building block 24 
 
 
 
Synthesis of β-Lactose octaacetate (18)5: Solid I2 (1.5 g, 5.8 mmol) was dissolved in 150 mL 
of Ac2O. After cooling the solution using cold water bath, D lactose monohydrate (20.0 g, 58.4 
mmol) was slowly added and to it. The reaction mixture was allowed to stir at room 
temperature for 1-2 hours and the reaction progress was monitored by TLC. After the 
completion of the reaction, reaction mixture was poured into a cold 5% sodium thiosulfate 
solution (300 mL) the mixture is allowed to warm up to room temperature for 20 min. The 
crude is diluted with DCM (500 mL) and the organic layer was washed with 5% NaHCO3 
solution. The organic layer was dried on vacuo. The product 18 was obtained in quantitative 
yield (39.0 g) and used for next step without purification. Spectroscopic data were in 
agreement with those reported in the literature.5 
 
 
 
 
Synthesis of β-D-Lactose heptaacetate (19)6: Compound 18 (30.0 g, 44.2 mmol) was dissolved 
in dry DMF (150 mL) and hydrazinium acetate (4.5 g, 48.6 mmol) was added to the reaction 
flask under nitrogen atmosphere. The reaction mixture was heated at 40 °C for 1 to 2 hours 
and progress of the reaction was monitored by thin layer chromatography (TLC) using ethyl 
acetate: hexane (7:3) as solvent system. After completion of the reaction, as indicated by TLC, 
DMF was removed in vacuo and saturated NaCl solution was added to the flask and extracted 
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using ethyl acetate. The combined organic layer was dried over Na2SO4 and concentrated on 
rotary evaporator. Crude mixture was purified by column chromatography using ethyl 
acetate: hexane (7:3) as eluent. (Rf = 0.3). Compound 19 was obtained in quantitative yield. 
Spectroscopic data were in agreement with those reported in the literature.6 
 
 
 
 
Synthesis of tertbutyl dimethylsilyl 2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl-(1-4)-2,3,6-
tri-O-acetyl-β–D-glucopyranoside (20)6: To the stirred solution of crude compound 19 (30.0 
g, 47.1 mmol) and imidazole (16.0 g, 235.6 mmol) in dry DMF (150 mL) was added the tert-
butyl dimethylsilyl chloride (8.5 g, 56.6 mmol). Reaction mixture was stirred at room 
temperature for 24 hours and then the volume of the reaction flask was reduced to half. The 
remaining reaction mixture was dissolved in 1.5 L of Et20 and washed with a saturated aq 
NH4Cl (3 × 200 mL) solution. The organic layer was dried over Na2SO4 and concentrated in 
vacuo. The crude product (28.0 g, 80% yield) was used for further steps without purification. 
TLC - 1:1 EtOAc-hexane; Rf 0.62. Spectroscopic data were in agreement with those reported 
in the literature.6 
 
 
 
 
Synthesis of tert-butyldimethylsilyl β-D-galactopyranosyl-(1-4)-α/β-D-glucopyranoside 
(21): Compound 20 (20.0 g, 26.6 mmol) was dissolved in dry MeOH (200 mL) and the reaction 
flask was cooled to -10 °C. Then 1 M NaOMe solution in methanol was added slowly to the 
reaction at -10 °C until the pH of the solution reached ~9 and then the reaction mixture was 
stirred at -10 °C overnight. Then the reaction mixture was neutralized using Amberlite IR – 
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120 acidic resins, filtered and concentrated under reduced pressure gave 12.0 g of compound 
21 which on crystallization in methanol/ethyl acetate (2:1) afforded pure α-form of 
compound 21. TLC (65:30:5 CHCl3: MeOH: H2O); Rf 0.42. 1H NMR (400 MHz, Deuterium 
Oxide) δ 5.24 (1 H, d, J 3.7), 4.70 (1 H, dd, J 11.2, 7.7), 4.48 (2 H, dd, J 8.0, 4.1), 4.04 – 3.51 (23 
H, m), 3.40 – 3.22 (1 H, m), 0.95-0.91 (5 H, s), 0.28 – 0.06 (3 H, m).13C NMR (101 MHz, 
Deuterium Oxide) δ 102.9, 97.1, 95.8, 92.9, 91.8, 78.8, 78.5, 78.4, 75.4, 74.8, 74.6, 74.4, 74.2, 
73.8, 72.6, 72.0, 71.4, 71.3, 71.2, 71.0, 70.1, 68.6, 61.0, 60.1, 60.0, 25.1.  
 
 
 
 
Synthesis of tert-butyldimethylsilyl 3-O-allyl-β-D-galactopyranosyl-(1-4)-α/β-D-
glucopyranoside (22): The mixture of compound 21 (α- form) (2.0 g, 4.0 mmol) and dibutyltin 
oxide (1.1 g, 4.6 mmol) in dry Toluene (80 mL) was heated at reflux for 4 hours while using 
dean stark trap to remove water from the reaction. Then toluene was removed completely 
on rotary evaporator and dry THF (50 mL) was added to the reaction flask. Then allyl bromide 
(3.9 mL, 46.3 mmol) followed by the addition of tetrabutylammonium iodide (0.8 g, 2.2 
mmol).The reaction mixture was then stirred at 60 °C for 14 hours and then cooled down to 
room temperature. THF was removed under reduced pressure and purification by column 
chromatography using ethyl acetate/methanol (15:1) as eluent yielded 22 (1.1 g) in 50 % yield. 
RF= 0.2. 1H NMR (400 MHz, Chloroform-d) δ 5.95 (1 H, ddt, J 17.2, 10.3, 5.8), 5.33 (1 H, dq, J 
17.2, 1.5), 5.22 (1 H, dt, J 10.3, 1.4), 5.15 (1 H, d, J 3.4), 4.78 (1 H, s), 4.50 (1 H, d, J 7.9), 4.27 
– 4.15 (2 H, m), 4.06 (1 H, d, J 3.2), 4.04 – 3.89 (3 H, m), 3.89 – 3.67 (6 H, m), 3.63 (2 H, t, J 
5.3), 3.54 (1 H, dd, J 9.7, 3.5), 3.40 (1 H, dd, J 9.5, 3.1), 3.25 (1 H, s), 2.96 (1 H, s), 2.33 (1 H, d, 
J 11.2), 0.91 (9 H, s), 0.12 (6 H, d, J 4.9); 13C NMR (101 MHz, Chloroform-d) δ 134.3, 118.2, 
103.1, 93.3, 80.4, 78.0, 77.3, 77.0, 76.7, 74.7, 72.8, 72.6, 71.2, 70.4, 69.5, 67.2, 62.4, 61.4, 
25.7, 18.0. HRMS (ESI): m/z calcd for C21H40O11Si [M+Na]+– 519.2236, found 519.2238. 
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Synthesis of tert-butyldimethylsilyl 3-O-allyl-4,6-O-benzylidene-β-D-galactopyranosyl-(1-
4)-α/β-D-glucopyranoside (23): Compound 22 (1.0 g, 1.8 mmol), benzaldehyde dimethyl 
acetal (0.4 g, 2.9 mmol) and p-toluenesulfonic acid monohydrate (0.03 g, 0.2 mmol) was taken 
in a round bottom flask and CH3CN was (10 mL) was added to it. The reaction mixture was 
stirred overnight at room temperature and after completion of the reaction; the reaction was 
neutralize with triethyl amine. The resulting mixture was concentrated on rotary evaporator. 
After that mixture was dissolved in ethyl acetate and washed with saturated NaCl solution. 
The organic phase was dried over sodium sulphate and concentrated under reduced pressure 
to give the crude product 23. The purification using column chromatography in 
ethylacetate/MeOH (15:1) as an eluent afforded the product in 75% yield (0.8 g). Rf=0.5. 1H 
NMR (400 MHz, Chloroform-d) δ 7.51 – 7.46 (2 H, m), 7.40 – 7.29 (3 H, m), 5.95 (1 H, ddt, J 
17.2, 10.3, 5.8), 5.51 (1 H, s), 5.33 (1 H, dq, J 17.2, 1.6), 5.22 (1 H, dq, J 10.3, 1.3), 5.18 (1 H, d, 
J 3.6), 4.56 (1 H, d, J 8.1), 4.34 – 4.15 (4 H, m), 4.09 – 4.01 (3 H, m), 3.99 – 3.92 (1 H, m), 3.88 
– 3.66 (5 H, m), 3.55 – 3.42 (3 H, m), 2.88 (1 H, t, J 7.1), 1.95 (1 H, d, J 9.9), 0.91 (9 H, s), 0.13 
(6 H, d, J 3.2); 13C NMR (101 MHz, Chloroform-d) δ 137.3, 134.6, 129.1, 128.3, 126.3, 118.0, 
103.3, 101.5, 93.1, 78.8, 77.3, 77.0, 73.1, 73.0, 72.8, 70.8, 70.6, 69.2, 68.5, 67.2, 61.4, 25.7.  
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Synthesis of tert-butyldimethylsilyl 2-O-acetyl-3-O-allyl-4,6-O-benzylidene-β-D-
galactopyranosyl-(1-4)-2,3,6-O-acetyl-α/β-D-glucopyranoside (24): Molecule 23 (0.7 g, 1.3 
mmol) was dissolved in 10 mL of pyridine/acetic anhydride (1:1). The catalytic amount of 
DMAP (0.008 g, 0.06 mmol) was added to the reaction flask and the reaction mixture was 
stirred at room temperature overnight. Then the reaction mixture was then concentrated in 
vaccuo and co-evaporated with toluene azeotropically. The compound was dried over 
vacuum and obtained in quantitative yield (0.96 g). The compound was used for next steps 
without further purification. Toluene/acetone (8:2); Rf =0.42. HRMS (ESI): m/z calcd for 
C36H52O15Si [M+Na]+– 775.2968, found 775.2964. 
 
 
 
 
Synthesis of 2-O-acetyl-3-O-allyl-4,6-O-benzylidene-β-D-galactopyranosyl-(1-4)-2,3,6-O-
acetyl-α/β-D-glucopyranose (39): Compound 24 (0.8 g, 1.1 mmol) was dissolved in 20 mL of 
anhydrous THF under argon atmosphere at -10 ◦C followed by the dropwise addition of 1M 
TBAF solution in THF (1.2 mL) was added dropwise to the flask. The reaction mixture turns 
yellow immediately after addition of TBAF. The reaction mixture was stirred at -10 ◦C for 2 
hour and after completion of reaction (monitored by TLC), the reaction mixture was 
neutralized with sat. aq. NH4HCO3 solution. During the neutralization process a colourless 
precipitate was formed which was taken up in DCM. The organic phase was subsequently 
washed with brine, dried over Na2SO4 and the solvent was removed in vacuo. The purification 
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of crude compound by column chromatography yielded the compound 39 as white foam in 
95% yield (0.65 g) using toluene/acetone (9:1). Rf = 0.7. 1H NMR (400 MHz, Chloroform-d) 
δ7.51 – 7.42 (2 H, m), 7.36 (3 H, d, J 7.0), 5.93 – 5.75 (1 H, m), 5.60 – 5.44 (2 H, m), 5.36 (1 H, 
t, J 3.5), 5.30 – 5.11 (3 H, m), 4.95 – 4.66 (1 H, m), 4.49 (1 H, d, J 10.1), 4.40 (1 H, t, J 8.1), 4.25 
– 3.99 (5 H, m), 3.81 – 3.63 (2 H, m), 3.51 (1 H, dd, J 10.1, 3.3), 3.36 (1 H, s), 3.31 (1 H, d, J 3.4), 
2.11 (3 H, s), 2.06 (9 H, d, J 2.0), 1.71 (1 H, s); 13C NMR (101 MHz, Chloroform-d) δ 170.65, 
170.41, 170.12, 168.99, 137.55, 134.59, 129.12, 128.21, 126.57, 117.24, 101.54, 101.33, 
101.25, 95.37, 90.24, 77.45, 77.33, 77.02, 76.70, 75.96, 75.90, 73.46, 73.21, 71.74, 71.22, 
70.48, 70.40, 69.29, 68.95, 68.60, 66.72, 62.33, 62.19, 20.82, 20.75, 20.64.  
 
 
 
 
Synthesis of 2-O-acetyl-3-O-allyl-4,6-O-benzylidene-β-D-galactopyranosyl-(1-4)-2,3,6-O-
acetyl-α/β-D-glucopyranosyl triflouro-N-phenylacetimidate (41): To a solution of 
hemiacetal compound 39 (0.44 g, 0.7 mmol) in dry DCM (10 mL) was added 2,2,2-trifluoro-N-
phenylacet-imidoyl chloride (223.5 µL, 1.4 mmol). The reaction mixture was cooled to 0 0C 
and to the cool solution Cs2CO3 (0.45 g, 1.4 mmol) was added. The reaction mixure was 
allowed to warm up to room temperature and stirred for 2 hours. Reaction progress monitor 
by TLC and on completion of the reaction, the reaction mixture was filtered over celite and 
the filtrate was concentrated in vacuo. The product was purified by column chromatography 
using toluene/acetone (8:2) as eluent and obtained 41 in quantitative yield (0.54 g) as 
colorless oil. 1H NMR (400 MHz, Chloroform-d) δ 7.48 (2 H, dd, J 7.7, 1.7), 7.36 (3 H, t, J 6.1), 
7.30 (2 H, t, J 7.8), 7.21 – 7.08 (3 H, m), 6.80 (2 H, d, J 7.2), 5.91 – 5.78 (1 H, m), 5.53 (2 H, d, J 
8.4), 5.31 – 5.14 (4 H, m), 5.10 (1 H, d, J 8.8), 4.55 – 4.37 (2 H, m), 4.30 (1 H, d, J 11.4), 4.23 (1 
H, d, J 3.3), 4.18 – 3.99 (5 H, m), 3.84 (1 H, q, J 9.8, 9.0), 3.51 (1 H, dd, J 10.0, 3.5), 3.37 (1 H, 
s), 2.36 (2 H, s), 2.12 (3 H, s), 2.09 (3 H, s), 2.06 (6 H, s), 1.57 (3 H, s); 13C NMR (101 MHz, 
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Chloroform-d) δ 190.7, 170.4, 170.1, 169.9, 168.9, 143.0, 137.3, 134.5, 129.2, 128.8, 128.2, 
126.6, 124.6, 119.4, 117.3, 101.5, 101.2, 77.5, 77.3, 77.0, 76.7, 75.3, 73.1, 71.3, 69.6, 69.1, 
68.7, 66.8, 61.7, 20.9, 20.7, 20.5, 1.0; HRMS (ESI): m/z calcd for C38H42F3NO15 [M+Na]+– 
832.2404, found 832.2398. 
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5.2.3 Synthesis of building block 31 
 
 
 
 
Synthesis of hexa-O-acetyl-D-lactal (25)7: To a suspension of D-lactose (1.00 g) in acetic 
anhydride (2.7 g, 9.0 mol equiv) was added 1.0 g of 31% HBr acetic acid at room temperature 
(the temperature was kept at room temperature while cooled by a water bath). Although the 
mixture was stirred at room temperature for 4 h, the solid lactose did not completely dissolve. 
Additional 31 % HBr/acetic acid (4.0 g, thus making an overall total of 6.7 mol equiv of HBr) 
was added and the resulting mixture was stirred overnight at room temperature, at which 
point all of the solid lactose went into solution. The reaction mixture was poured onto a 
suspension of pulverized CuSO4.5H2O (0.18 g) and zinc (7.3 g) in a solution of water (10 mL) 
and acetic acid (15 mL) containing sodium acetate (5.5 g). The resultant reaction mixture was 
stirred vigorously at room temperature for 1.5 h in a bath of running tap water. The mixture 
was then filtered and the solid collected was washed with ethyl acetate (100 mL) and then 
with water (100 mL). The organic layer of the filtrate was washed successively with saturated 
aqueous NaHCO3 (100 mL) and brine (100 mL), and then dried (Na2SO4). The solvent was 
removed under reduced pressure to provide a crude solid which was purified by silica gel flash 
column chromatography using 50% ethyl acetate in hexanes as the eluent to afford hexa-O-
acetyl- D-lactal (25) (1.2 g, 86%) as a colourless solid:  
Spectroscopic data were in agreement with those reported in the literature.7 
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Synthesis of 1-O-acetyl-3,6-di-O-acetyl-4-O-(2,3,4,6-tetra-O-acetyl-β-D-gulcopyranosyl)-2-
deoxy-2-iodo-α-D-mannopyranose (26)8: In a 200 mL acetic acid solution, glycal 25 (10.0 g, 
17.8 mmol), Cu(OAc)2 (3.6 g, 19.6 mmol), and I2 (5.4 g, 21.4 mmol) were added in respective 
order. The resulting mixture was stirred at 80 ◦C overnight under argon atmosphere. Then the 
reaction was evaporated to dryness under reduced pressure and the obtained residue was 
diluted with DCM (500 mL). The organic layer was washed with aq. NaHCO3 (150 mL), aq. 
Na2S2O3 (150 mL) and brine (150 mL) and dried over Na2SO4, and concentrated. The crude 
residue was purified by silica gel column chromatography (n-hexane : ethyl acetate = 2/1) to 
yield the compound X as white solid ( 9.3 g, 70%). Spectroscopic data were in agreement with 
those reported in the literature.8 
 
 
 
 
Synthesis of 3,6-di-O-acetyl-4-O-(2,3,4,6-tetra-O-acetyl-β-D-gulcopyranosyl)-2-deoxy-2-
iodo-α-D-mannopyranosyl azide (27)8: To the solution of iodoacetate 26 (9.0 g, 12.0 mmol) 
and TMSN3 (1.9 mL, 14.5 mmol) in dry DCM (100 mL), TMSOTf (435 µL, 2.4 mmol) was added 
at 0 oC under argon atmosphere. The reaction mixture was gradually warmed to room 
temperature and then stirred overnight. The resulting mixture was then diluted with DCM 
(400 mL) and the organic phase was washed with aq. NaHCO3 (150 mL) dried over Na2SO4. 
The organic layer was concentrated on rotary evaporator and the resulting residue was 
purified by silica gel column chromatography (n-hexane/ethyl acetate = 1:1) to afford 
compound X as a white solid (7.0 g, 80%) as white solid. Spectroscopic data were in agreement 
with those reported in the literature.8 
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Synthesis of ethyl [3,6-di-O-acetyl-4-O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-2- 
aminotriphenylphosphonium-2-deoxy-1-thio-β-D-glucopyranoside] iodide (28)8: In 100 mL 
of dry DCM, compound 27 (7.0 g, 9.6 mmol) and ethanethiol (831 μL, 11.5 mmol) and 4 Å MS 
were added under argon. The reaction mixture was then cooled down to 0 oC and stirred for 
30 min. Then a solution of PPh3 (2.6 g 10.1 mmol) in DCM (5 mL) was added dropwise. The 
reaction mixture was allowed to warm gradually to room temperature and further stirred for 
additional 12 h. The molecular sieves was filtered off through a pad of Celite and the filtrate 
was concentrated under reduced pressure. The resulting crude residue was purified by silica 
gel column chromatography using ethyl acetate: ethanol (10/1) as eluent to yield the 
compound 28 (9.4 g, 95%) as yellow foam. The resulting Lanfont intermediate was stored and 
next steps were carried out in batches when required. Spectroscopic data were in agreement 
with those reported in the literature.8 
 
 
 
 
Synthesis of Ethyl 3,6-O-di-acetyl-4-O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-2-
deoxy-2-ohydroxylbenzylideneamino-1-thio-β-D-glucopyranoside (29)8: To a mixture of 
compound 28 (1.0 g, 1.0 mmol) and salicylaldehyde (1 mL in 2 mL of chlorobenzene in a 
Microwave tube, Et3N (2 mL) was added. Then the reaction was irradiated with 150 W of 
microwave energy at 140 ◦C for 30 min. The resulting reaction mixture was then transferred 
into a round bottom flask and concentrated in vacuo. Purification by silica gel column 
chromatography (n-hexane/ethyl acetate = 1:1) afforded compound 11 (0.6 g, 80 %) as foam. 
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The scale of the reaction was reduced due to the size limitation of microwave set-up. 
Spectroscopic data were in agreement with those reported in the literature.8 
 
 
 
 
Synthesis of ethyl 3,6-O-di-acetyl-4-O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-2-
deoxy-2-amino-1-thio-β-D-glucopyranoside hydrochloride (30)8: To a solution of compound 
29 (3.0 g, 4.0 mmol) in a mixture of acetone/DCM (8:1, 10 mL), aq. 3 M HCl solution (1.4 mL, 
4.1 mmol) was added. The reaction mixture was then stirred for 1 h at room temperature and 
the progress of the reaction was monitored using TLC. On complete conversion of the starting 
material, the solution was diluted with toluene (6 mL) and the solvent was removed under 
vacuo. The residue was purified by silica gel column chromatography using ethyl 
acetate/ethanol (20:1) to yield compound 12 (1.9 g, 72%) as foam. Spectroscopic data were 
in agreement with those reported in the literature.8 
 
 
 
 
Synthesis of ethyl 3,6-O-di-acetyl-4-O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-2-
deoxy-2-N-Troc-1- thio-β-D-glucopyranoside (31)8: To a solution of 30 (0.5 g, 0.8 mmol) and 
Et3N (511 μL, 3.7 mmol) in DCM/H2O (1:1, 30 mL), TrocCl (1 mL, 7.9 mmol) was added. The 
reaction was stirred then overnight at room temperature. The resulting solution was diluted 
with DCM (150 mL) and washed with aq. NaHCO3 (100 mL) and brine (100 mL). The organic 
layer was dried over Na2SO4, filtered, and concentrated over vacuo. The crude residue was 
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purified by silica gel column chromatography using hexane/ethyl acetate (1/1) to afford 
compound 14 (0.5 g, 77%) as foam. Spectroscopic data were in agreement with those 
reported in the literature.8 
 
 
 
 
Synthesis of ethyl-3,6-O-di-acetyl-4-O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-2-
deoxy-2-N phthalimido-1-thio-β-D-glucopyranoside (32)8: To a solution of 30 (0.95 g, 1.4 
mmol) in pyridine (30mL), Et3N (247 μL, 1.8 mmol) was added. The reaction mixture was 
stirred for 30 minutes followed by the addition of phthalic anhydride (0.2 g, 1.6 mmol). The 
resulting solution was stirred for 2 hours and then a second portion of phthalic anhydride (0.2 
g, 1.6 mmol) and Et3N (247 μL, 1.8 mmol) were added. Then the resulting reaction mixture 
was stirred for additional 2 hours and then the reaction was quickly moved to an preheated 
oil bath at 90 oC followed by the addition of Ac2O (10 mL). The mixture was then stirred for 
another 30 min at 90 oC and after 30 minutes, the solution was concentrated in vacuo. The 
resulting residue was dissolved in DCM (100 mL) and the organic layer was washed with aq. 1 
N HCl (70×3), water (60 mL), aq. NaHCO3 (50 mL), and brine (50 mL). The organic phase was 
dried over Na2SO4, filtered, and concentrated under reduced pressure. The crude residue was 
purified by silica gel column chromatography using hexane/ethyl acetate (1:1) to yield 
compound 13 (0.96 g, 20%) as white solid. Spectroscopic data were in agreement with those 
reported in the literature.8 
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5.2.4 Synthesis of building block 38 
 
 
 
 
Synthesis of 2,3,4,6-tetra-O-acetyl-α-D-galactopyranosyl bromide (33)9: To the penta-acetyl 
galactose (2.5 g, 6.4mmol) was added 40 mL 33% HBr-AcOH solution and the resulting mixture 
was stirred at room temperature for 1h. Then the resulting solution was diluted with DCM 
(100 mL) and transferred to a separatory funnel containing ice. The ice was allowed to melt 
and thehe organic phase was washed with ice water until neutral pH was achieved. The 
organic phase was then dried over Na2SO4, filtered, and concentrated to give compound 33 
as a syrup in good yield: 88% (2.3 g). The product was used directly in the next step without 
purification. 
 
 
 
 
Synthesis of 3,4,6-tri-O-acetyl-1,2-O-(1-methoxyethylidene)-α-D-galactopyranoside (34)9: 
Compound 33 (2.0 g, 4.86 mmol) and 2,4,6-collidine (0.9 g, 7.3 mmol) were dissolved in dry 
DCM (20 mL). Anhydrous methanol (10 mL) was then added in one portion followed by 
followed by the addition of tetrabutylammonium bromide (0.8 g, 2.4 mmol). The resulting 
mixture was stirred at room temperature for 12 hour. The mixture was diluted with DCM and 
water. The aqueous portion was extracted with DCM (3x50 mL). The combined organic 
portion was dried over anhydrous Na2SO4, filtered, concentrated, and washed with hexanes 
to give compound 34 as a white solid in good yield (92%., 1.6 g). The compound was used for 
next steps without further purification. 
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Synthesis of 1,2-O-(1-methoxyethylidene)-α-D-galactopyranoside (35)10: To a solution of 34 
(1.00 g, 2.7 mmol) in dry MeOH (20 mL), 0.4 M NaOMe in MeOH (1.0 mL, 0.5 mmol) was 
added. After 30 min the reaction mixture was diluted with MeOH and neutralized with 
AMBERLITE® resin (H+ form). The mixture was then filtered and the solvent was removed in 
vacuo, affording compound 35 as a white solid (0.6 g, quant).  
 
 
 
 
 
Synthesis of 3,4,6-tri-O-benzyl-1,2-O-(1-methoxyethylidene)-α-D-galactopyranoside (36)10: 
To a solution of 35 (0.5 g, 2.1 mmol) and benzyl bromide (1.2 mL, 10.6 mmol) in dry DMF (50 
mL), sodium hydride (0.25 g, 10.6 mmol) was slowly added. The reaction mixture was then 
stirred for 3 hours and then after 3 h the reaction mixture was carefully quenched by adding 
MeOH (10 mL). The reaction mixture was then concentrated in vacuo and the crude residue 
was diluted with H2O. The aqueous solution was extracted with DCM (3 x 20 mL). The 
combined organic layers were washed with brine, dried over Na2SO4, concentrated in vacuo, 
and purified using flash chromatography Hexane:EtOAc (8:2  to 7:3 + 1% TEA) to obtain the 
36 as a colourless oil (0.7 g, 65%). 
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Synthesis of 2-O-acetyl-3,4,6-tri-O-benzyl-D-galactopyranose (37)10: Solution of 36 (0.7 g, 
1.3 mmol) in acetone: H2O (7:3, 10 mL) was cooled to 0 °C and p-TsOH (0.034 g, 0.4 mmol) 
was added to the flask. The reaction was then stirred for 2 h and then the reaction mixture 
was neutralized with triethyl amine and concentrated in vacuo. The crude residue was 
purified by flash chromatography (Hexane: AcOEt; 7:3) to obtain yield compound 37 (0.5 g, 
95%). 
 
 
 
 
Synthesis of 2-O-acetyl-3,4,6-tri-O-benzyl-β-D-galactopyranosyl trifluoro-N-
phenylacetimidate (38)9: To a solution of 1-hydroxy sugar 37 (0.5 g, 1.0 mmol) in dry DCM 
(10 mL) was added 2,2,2-trifluoro-N-phenylacetimidoyl chloride (0.42 g, 2.0 mmol). The 
reaction mixture was cooled to 0 oC and to the cool solution Cs2CO3 (0.66 g, 2.0 mmol) was 
added. The reaction mixture was allowed to warm up to room temperature and stirred for 2 
hours. Reaction progress monitor by TLC and on completion of the reaction, the reaction 
mixture was filtered over celite and the filtrate was concentrated in vacuo. The product was 
purified by column chromatography using toluene/acetone (8:2) as eluent and obtained in 
95% (0.6 g) yield as colourless oil.  
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5.2.5 Combining the Fragments 
 
 
Synthesis of Trisaccharide (5): A solution of donor 41 (0.2 g, 0.26 mmol) and acceptor 46 (0.17 
g, 0.31 mmol) in dry DCM (5 mL) was cooled to 0 oC and then TMSOTf (4.7 µL, 0.03 mmol) was 
added slowly to the reaction under argon atmosphere. The resulting reaction mixture was 
stirred at 0 °C and after completion of reaction; the reaction was quenched by triethyl amine. 
The reaction mixture was dried over vacuo and purification by silica get column 
chromatography using toluene: acetone (8/2) as eluent afforded trisaccharide 5 in 80 % yield 
(0.24 g).RF =0.5. 1H NMR (400 MHz, Chloroform-d) δ 7.57 (1 H, d, J 8.7), 7.51 – 7.43 (6 H, m), 
7.42 – 7.29 (9 H, m), 7.22 (4 H, d, J 7.6), 5.83 (1 H, ddd, J 22.7, 10.7, 5.5), 5.50 (1 H, s), 5.26 (1 
H, d, J 1.6), 5.24 – 5.13 (4 H, m), 5.02 – 4.94 (2 H, m), 4.89 (1 H, d, J 9.8), 4.62 (1 H, d, J 9.8), 
4.52 (2 H, q, J 12.2), 4.43 (1 H, d, J 11.1), 4.37 – 4.23 (4 H, m), 4.20 (1 H, d, J 3.3), 4.15 – 3.94 
(6 H, m), 3.74 (1 H, t, J 9.5), 3.70 – 3.55 (3 H, m), 3.54 – 3.33 (7 H, m), 3.31 (1 H, s), 2.08 (3 H, 
s), 2.03 (6 H, s), 1.92 (3 H, s), 1.63 (2 H, s); HRMS (ESI): m/z calcd for C60H71N3O20 [M+Na]+– 
1176.4529, found 1176.4534. 
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Synthesis of compound 42: The trisaccharide 5 (0.4 g, 0.3 mmol) was dissolved in dry THF (1.5 
mL) under nitrogen and the reaction flask was evacuated. Iridium catalyst (0.03 g, 0.03 mmol) 
was added to the flask following the evacuation of the flask. The reaction mixture was stirred 
at room temperature. A balloon of H2 gas was attached and this reaction was monitored until 
the red color of the solution turned to pale yellow. H2 balloon was then removed and the flask 
was flushed with Argon gas and stirred for another 6 hours. The resulting solution was 
concentrated and dissolved in 80% THF in water (4.5 mL) followed by the addition of I2 (0.17 
g, 0.6 mmol). The resulting solution was stirred at room temperature for an hour, quenched 
by addition of saturated sodium thiosulfate solution, and washed with sodium bicarbonate, 
brine and water. The residue was then concentrated and evaporated then purified by Flash 
Chromatography (Tol/acetone-8:2; RF= 0.2) to afford 42 in 85% yield (0.3 g) over 2 steps. 1H 
NMR (400 MHz, Chloroform-d) δ 7.44-7.39 (6 H, m), 7.37 – 7.27 (5 H, m), 7.25 – 7.08 (9 H, m), 
5.46 (1 H, s), 5.19 – 5.09 (2 H, m), 4.99 – 4.81 (4 H, m), 4.57 (1 H, d, J 9.8), 4.47 (2 H, q, J 12.2), 
4.38 (1 H, d, J 11.1), 4.35 – 4.20 (4 H, m), 4.14 – 4.08 (1 H, m), 4.09 – 3.88 (4 H, m), 3.70 (1 H, 
t, J 9.5), 3.63 – 3.30 (11 H, m), 2.47 (1 H, d, J 11.2), 2.30 (1 H, s), 2.04 (6 H, s), 2.01 (3 H, s), 1.87 
(3 H, s); 13C NMR (101 MHz, Chloroform-d) δ 170.4, 170.3, 170.2, 169.6, 138.7, 138.1, 137.7, 
137.3, 129.5, 128.9, 128.6, 128.4, 128.2, 127.9, 127.8, 127.6, 127.5, 126.5, 103.2, 101.8, 
100.9, 100.1, 82.8, 81.4, 77.4, 77.0, 76.7, 76.3, 75.7, 75.4, 75.1, 74.6, 74.4, 73.5, 72.8, 72.5, 
72.5, 72.1, 72.0, 68.9, 68.5, 66.6, 66.6, 62.4, 48.3, 29.3, 20.9, 20.8, 20.7; HRMS (ESI): m/z calcd 
for C57H67N3O20 [M+Na]+– 1136.4216, found 1136.4220. 
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Synthesis of 4: Acceptor 42 (0.15 g, 0.13 mmol) and donor 31 (0.13 g, 0.16 mmol) were 
dissolved in dry CH2Cl2 (2 mL) together with 4 Å molecular sieves (0.2 g). The mixture was 
stirred for 1 hour, then NIS (0.06 g, 0.3 mmol) was added and the mixture was cooled to -20 
°C. TfOH (9.5 μL, 0.1 mmol) was then dropped and the reaction was stirred for 30 minutes at 
the same temperature, then quenched with Et3N, filtered over Celite and evaporated in 
vacuo. Purification by flash column chromatography (Tol/Acetone, 9:1 → 7:3, v/v) gave 4 (0.2 
g, 80%) as a white foam. Rf = 0.34, Tol/Acetone 7:3. 1H NMR (400 MHz, Chloroform-d) δ 8.58 
(1 H, s), 7.48 – 7.40 (6 H, m), 7.38-7.32 (4 H, m), 7.32 – 7.13 (10 H, m), 5.50 (1 H, s), 5.38 – 
5.29 (2 H, m), 5.18 – 5.04 (5 H, m), 4.98 – 4.91 (3 H, m), 4.86 (1 H, d, J 9.9), 4.79 – 4.65 (3 H, 
m), 4.62 – 4.56 (2 H, m), 4.54 – 4.43 (4 H, m), 4.40 (1 H, d, J 11.1), 4.31 (1 H, d, J 7.8), 4.28 – 
4.18 (4 H, m), 4.12 – 3.92 (8 H, m), 3.86 – 3.81 (1 H, m), 3.78 – 3.44 (10 H, m), 3.40 – 3.31 (4 
H, m), 3.29 (1 H, s), 2.11 (3 H, s), 2.05 (6 H, d, J 2.3), 2.02 (9 H, s), 1.97 (6 H, q, J 5.9, 4.4), 1.94 
(3 H, d, J 2.0), 1.90 (3 H, s), 1.86 – 1.81 (2 H, m), 1.23 (2 H, s); 13C NMR (101 MHz, Chloroform-
d) δ 189.16, 177.69, 170.58, 170.38, 170.20, 170.14, 169.63, 169.06, 168.93, 153.86, 138.65, 
138.14, 137.65, 129.18, 128.92, 128.53, 128.34, 128.15, 127.87, 127.75, 127.61, 127.48, 
126.52, 103.22, 101.26, 101.08, 100.97, 99.96, 95.39, 82.74, 81.42, 79.17, 77.39, 77.07, 76.75, 
75.74, 75.52, 75.08, 74.54, 74.36, 73.44, 72.72, 72.49, 72.08, 71.47, 70.90, 70.72, 69.75, 
69.23, 68.90, 68.49, 66.68, 66.58, 62.36, 61.10, 60.86, 56.02, 31.64, 29.60, 29.31, 20.98, 
20.88, 20.63; HRMS (ESI): m/z calcd for C84H101Cl3N4O37 [M+Na]+– 1885.5108, found 
1885.5115. 
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Synthesis of 43: To the solution of pentasccharide 4 (0.2 g, 0.05 mmol) was dissolved in dry 
THF (2 mL) and then 1 M TBAF in THF (322 µl) was added to the flask. The mixture was stirred 
at room temperature for 2 hours and then diluted with EtOAc. The resulting solution was 
washed with water, dried over MgSO4 and filtered. Solvent was removed under reduced 
pressure and the crude product was used for next step without further purification. 
The crude residue was dissolved in 2 mL of acetic anhydride/pyridine (1:1) and the resulting 
solution was stirred for 5 hours. Then the solvent was removed in vacuo. Purification by flash 
column chromatography using toluene: Acetone (7: 3) as eluent afforded the N-acetyl product 
43 as a white solid in 90 % yield (0.16 g). 1H NMR (400 MHz, Chloroform-d) δ 7.47 (6 H, d, J 
6.2), 7.37 (4 H, d, J 6.6), 7.34 – 7.16 (10 H, m), 5.88 (1 H, d, J 8.1), 5.50 (1 H, s), 5.36 (1 H, d, J 
3.4), 5.31 (1 H, d, J 8.2), 5.21 – 5.07 (4 H, m), 5.02 – 4.87 (5 H, m), 4.64 (2 H, t, J 10.5), 4.59 – 
4.40 (4 H, m), 4.33 (3 H, dd, J 16.4, 7.7), 4.28 – 4.21 (2 H, m), 4.19-4.06 (4 H, m), 4.04 – 3.95 
(3 H, m), 3.87 (1 H, t, J 6.9), 3.81 – 3.73 (2 H, m), 3.73 – 3.56 (5 H, m), 3.55 – 3.47 (2 H, m), 
3.44-3.35 (5 H, m), 3.33 (1 H, s), 2.36 (1 H, s), 2.15 (3 H, s), 2.09 (6 H, d, J 7.4), 2.05 (12 H, d, J 
3.0), 1.98 (6 H, s), 1.93 (4 H, s), 1.90 (3 H, s); 13C NMR (101 MHz, Chloroform-d) δ 170.5, 170.4, 
170.3, 170.2, 170.1, 170.0, 169.8, 169.6, 169.2, 169.2, 138.6, 138.1, 137.8, 137.7, 129.1, 
128.9, 128.5, 128.4, 128.3, 128.2, 127.9, 127.7, 127.6, 127.5, 126.5, 103.2, 101.3, 100.9, 
100.7, 100.6, 99.9, 82.8, 81.4, 78.2, 77.5, 77.1, 76.8, 75.7, 75.4, 75.1, 74.5, 74.3, 73.4, 72.8, 
72.5, 72.1, 70.8, 70.4, 70.4, 69.1, 68.9, 68.5, 66.7, 66.6, 62.3, 62.0, 60.8, 54.1, 48.3, 29.3, 23.2, 
21.0, 20.9, 20.6, 20.5. 
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Synthesis of 44: The N-acetylated pentasaccharide 43 (0.05 g) was dissolved in CH3OH (1 mL) 
and to the solution was added 1 M CH3ONa in CH3OH until pH reached 12. The mixture was 
then stirred at room temperature for 12 h and then neutralized with Amberlyst 15 H+ resin, 
and filtered. The filtrate was concentrated under vacuum. The residue was purified on 
Sephadex LH-20 GEL column with CH3OH as the eluent to give a white solid.  
The obtained solid was dissolved in CH3OH and H2O (v/v, 4:1, 1 mL) and then mixed with 
Pd(OH)2 (10 mol %). After the mixture was stirred under a H2 atmosphere at 50 Psi for 36 h. 
After that, it was filtered, and concentrated to give a residue, which was purified on Sephadex 
G-25 gel column with H2O as the eluent to produce the linear chain pentasaccharide 44 as a 
white solid. 1H NMR (400 MHz, Deuterium Oxide) δ 5.53 (3 H, d, J 3.6), 5.31 (1 H, t, J 7.7), 
5.10 – 4.97 (3 H, m), 4.64 – 4.43 (18 H, m), 4.41 – 4.25 (24 H, m), 4.24 – 3.95 (23 H, m), 3.92-
3.90 (6 H, m), 3.75 (1 H, q, J 7.4), 3.47 (1 H, s), 3.33 (1 H, d, J 19.2), 3.28 – 3.10 (1 H, m), 2.65 
– 2.58 (3 H, m). 
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5.3 NMR Spectra 
 
 
NMR Spectra of compound 15 
 
 
 
 
 
 
1H NMR of compound 15 
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13C NMR of compound 15 
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NMR Spectra of compound 46 
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13C NMR of compound 46 
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NMR Spectra of compound 21 
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13C NMR of compound 21 
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NMR Spectra of compound 22 
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13C NMR of compound 22 
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NMR Spectra of compound 23 
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13C NMR of compound 23 
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NMR Spectra of compound 39 
 
 
 
 
 
1H NMR of compound 39 
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13C NMR of compound 39 
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NMR Spectra of compound 41 
 
 
 
 
1H NMR of compound 41 
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13C NMR of compound 41 
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NMR Spectra of compound 5 
 
 
 
 
 
 
1H NMR of compound 5 
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13C NMR of compound 5 
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1H-1H COSY NMR of compound 5 
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1H-13C HSQC NMR of compound 5 
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NMR Spectra of compound 42 
 
 
 
 
 
 
1H NMR of compound 42 
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13C NMR of compound 42 
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1H-1H COSY NMR of compound 42 
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1H-13C HSQC NMR of compound 42 
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NMR Spectra of compound 4 
 
 
 
 
 
1H NMR of compound 4 
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13C NMR of compound 4 
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1H-1H TOCSY NMR of compound 4 
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1H-13C HSQC NMR of compound 4 
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NMR spectra of compound 43 
 
 
 
 
 
 
1H NMR of compound 43 
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13C NMR of compound 43 
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NMR Spectra of compound 44 
 
 
 
 
 
 
1H NMR of compound 44 
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5.4 Mass Spectra 
 
 
HRMS of compound 22 
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HRMS of compound 24 
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HRMS of compound 41 
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HRMS of compound 5 
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HRMS of compound 42 
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HRMS of compound 4 
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